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ABSTRACT 
 
Cancers often resurrect embryonic molecular programs to promote disease 
progression. In melanomas, which are tumors of the neural crest (NC) lineage, a 
molecular signature of the embryonic NC is often reactivated. These NC factors 
have been implicated in promoting pro-tumorigenic features like proliferation, 
migration and therapy resistance. However, the molecular mechanisms that 
establish and maintain NC identities in melanomas are largely unknown. 
Additionally, whether the presence of a NC identity has any clinical relevance for 
patient melanomas is also unclear. Here, using comparative genomic 
approaches, I have a) identified a novel role for GDF6-activated BMP signaling in 
reawakening a NC identity in melanomas, and b) identified a NC signature as a 
clinical predictor of melanoma progression.  
 Like the genomes of many solid cancers, melanoma genomes have 
widespread copy number variations (CNV) harboring thousands of genes. To 
identify disease-promoting drivers amongst such huge numbers of genes, I used 
a comparative oncogenomics approach with zebrafish and human melanomas. 
This approach led to the identification of a recurrently amplified oncogene, GDF6, 
that acts via BMP signaling to invoke NC identities in melanomas. In maintaining 
this identity, GDF6 represses the melanocyte differentiation gene MITF and the 
proapoptotic factor SOX9, allowing melanoma cells to remain undifferentiated 
and survive. Functional analysis in zebrafish embryos indicated a role of GDF6 in 
  
VI 
blocking melanocyte differentiation, suggesting that the developmental function 
of GDF6 is reiterated in melanomas. In clinical assessments, a major fraction of 
patient melanomas expressed high GDF6, and its expression correlated with 
poor patient survival. These studies provide novel insights into regulation of NC 
identities in melanomas and offer GDF6 and components of BMP pathway as 
targets for therapeutic intervention.  
 In additional studies, I wanted to test whether a broader NC identity in 
melanomas had any clinical relevance. In these studies, I performed 
transcriptome analysis of zebrafish melanomas and derived a 15-gene NC 
signature. This NC gene signature positively correlated with the expression of 
SOX10, a known NC marker in human melanomas. Patients whose melanomas 
expressed this signature showed poor overall survival. These findings identify an 
important predictive signature in human melanomas and also illuminate the 
clinical importance of NC identity in this disease.  
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CHAPTER I 
INTRODUCTION 
Melanoma 
Overview 
Melanoma is the most fatal skin cancer, with a growing incidence. It 
originates from melanocytes, which are melanin-producing cells present in the 
basal layer of skin epidermis. Melanin provides color to the skin and hair (Lin and 
Fisher, 2007) and absorbs ultraviolet (UV) rays from the sun, thereby protecting 
other cells in the deep skin layers from UV-induced DNA photodamage. In 2012, 
232,000 cases of melanoma, resulting in 55,000 deaths, were reported 
worldwide. In the United States, approximately 9,000 people die due to 
melanoma annually (Guy, 2015). In the last four decades, the frequency of 
melanomas has increased by 15-fold (Weinstock, 2001). 
The progression of melanoma can be simply defined as a stepwise 
process (Figure 1.1)(Miller and Mihm, 2006). On exposure to mutagens such as 
UV rays, normal melanocytes undergo uncontrolled proliferation to form benign 
lesions called moles or nevi. Mutation-laden melanocytes can also transform into 
malignant melanomas, either through nevus formation or independently. In the 
early stages, melanoma growth is confined to the epidermis. As the disease 
progresses, melanomas invade through the basement membrane into the dermis 
and the underlying subcutaneous tissues. Eventually, the cancer cells 
metastasize to lymph nodes and other distant sites of the body. When diagnosed  
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Figure 1.1: Progression of melanoma 
When melanocytes are exposed to mutagens, they form either benign nevi or 
malignant melanomas. Melanomas initially proliferate within the basal layer of the 
skin. Upon further disease progression, melanoma cells firstly invade into the 
basement membrane and the underlying subcutaneous tissue and eventually 
they metastasize to distant sites using blood and lymphatic vessels.  
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at early stages, patients with melanoma have more than 90% chance of survival; 
however, advanced-stage melanoma patients with distant metastasis have low 
chances of survival (Eggermont et al., 2016; Noone et al., 2017). 
Melanoma therapeutics have greatly advanced in the past few years. Until 
a decade ago, chemotherapy was the only mode for treating patients with 
advanced-stage melanomas; however, these patients had poor survival rates 
because their melanomas were highly resistant to chemotherapeutic treatment. 
Several recent functional genomic studies have yielded targeted and immune 
therapies for melanoma treatment (Bollag et al., 2010; Hodi et al., 2010), with 
excellent clinical benefits. The survival rate of patients with advanced-stage 
melanomas has increased from 18% to approximately 40% (Eggermont et al., 
2016; Noone et al., 2017). Although significant progress has been made in 
melanoma therapy, a considerable number of patients either do not respond or 
show resistance to current therapies. Hence, most efforts in melanoma research 
are currently focused on improving current treatment modes, testing 
combinatorial therapeutic approaches, targeting drug resistance mechanisms, 
and identifying new therapeutic targets. 
 
Genomic Changes in Melanomas 
Comprehensive screening of the melanoma genome through whole-
genome and exome sequencing has demonstrated extensive genetic alterations 
and helped identify novel cancer genes (Akbani, 2015; Berger et al., 2012; Hodis 
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et al., 2012; Krauthammer et al., 2012). Oncogenomic studies on several human 
cancers have identified melanomas as one of the most highly mutated cancers 
(Lawrence et al., 2013); several types of genetic alterations, including base 
substitution mutation, copy number variation (CNV), and translocation, have 
been identified. A metastatic melanoma genome harbors approximately 33,000 
base substitutions (Pleasance et al., 2010). A majority of these base substitutions 
are C>T/G>A transitions, a mutational spectrum caused by UV light exposure. 
Among this large pool of mutations, researchers have used computational and 
functional tools to distinguish disease-promoting driver gene mutations from 
randomly altered passenger gene changes that do not affect disease 
progression. These studies have led to the identification of recurrent mutations in 
BRAF, NRAS, PTEN, CDKN1A, and P53 mutations in melanoma and have (1) 
identified novel oncogenes and tumor suppressor genes; (2) revealed the role of 
the mitogen-activated protein kinase (MAPK), mTOR, p53, and other pathways in 
melanoma progression; and (3) enabled targeted therapy approaches for 
melanoma by using small molecular inhibitors, such as vemurafenib (mutant 
BRAFV600E inhibitor) and dabrafenib (MEK inhibitor). 
The melanoma genome also harbors numerous CNVs. Approximately 
10% of the melanoma genome, comprising approximately 2,000 genes, 
undergoes recurrent CNV (Beroukhim et al., 2010; Lin et al., 2008). Among these 
genes, only a few have been predicted to be disease-promoting drivers. In the 
regions of focal CNVs, consisting of few altered genes, several driver genes have 
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been identified; for instance, the presence of MITF, CCND1, BRAF, CDKN2A, 
and PTEN in the focal CNV regions of the melanoma genomes has enabled the 
identification and validation of their roles in melanomagenesis (Ghosh and Chin, 
2009; Lin et al., 2008; Shi et al., 2012; Vizkeleti et al., 2012). However, 
melanomas also harbor broad CNVs including the amplification or deletion of an 
entire chromosome or an arm of a chromosome (Lin et al., 2008). In these cases, 
numerous genes within these intervals confound the identification of the driver 
genes (Figure 1.2). Thus, the identification of these drivers may aid in 
understanding the biology of melanomas further and provide new therapeutic 
targets. 
 
Roles of Developmental Mechanisms in Melanoma Progression 
 In addition to identifying new cancer genes, genomic studies have 
reported changes in the cellular identity of tumor cells to a more precursor-like 
state (Mack et al., 2016; Wong et al., 2015). Melanomas are derivatives of the 
neural crest (NC) lineage because they invoke NC identities (Maguire et al., 
2015; Shakhova, 2014). NC cells are multipotent embryonic cells that transform 
to neurons, glia, cartilage, and melanocytes. These cells can self-renew and 
migrate, thus enabling them to generate distinct cell types and populate different 
regions of the embryo. A complex network of signaling pathways orchestrates 
these processes in these cells. The differentiated cell types (e.g., melanocytes) 
subsequently turn off these pathways because they lack the need to self-renew  
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Figure 1.2: Driver and passenger genes in regions of CNV 
Melanoma genomes harbor focal and broad regions of recurrent CNVs. In focal 
CNV regions, driver genes are found amongst a small number of passenger 
genes as compared to broad CNV regions, which harbor driver genes amongst a 
large number of passenger genes.   
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or migrate. However, some of these developmental pathways are reactivated in 
NC lineage-derived tumors, such as melanomas (Maguire et al., 2015). This 
activation confers protumorigenic properties, such as self-renewal, proliferation, 
and migration properties, to the tumor cells. 
Several factors expressed in NC cells are dysregulated in melanomas, 
and these factors contribute to melanoma progression in multiple ways. Early 
studies from the Weinberg lab reported a role of the NC factor Slug in promoting 
EMT to enable melanoma metastasis (Gupta et al., 2005). Subsequently, several 
embryonic factors regulating EMT, such as SNAIL and TWIST, were reported to 
be associated with melanoma metastasis (Caramel et al., 2013). Notably, a 
reason that melanomas are believed to be so metastatic is the inherent nature of 
the NC-derived cells to migrate. Studies from the Sommer lab also indicated a 
role of the NC factors SOX10 and SOX9 in regulating tumor cell survival 
(Shakhova et al., 2015; Shakhova et al., 2012). Other NC factors such as BRN3a 
and PAX3 also promote cell survival; loss of these factors caused apoptotic cell 
death in melanoma cells (Eccles et al., 2013; Hohenauer et al., 2013). Thus, 
considering this wide variety of roles of NC factors, developmental signaling is a 
crucial part of melanoma progression. 
Melanoma cells are highly plastic in nature; this plasticity is potentially 
regulated by the developmental program regulating melanocyte differentiation. 
Recent studies have indicated that melanoma cells undergo a process called 
“phenotype switching,” wherein tumor cells shuttle between a proliferation-
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promoting differentiated state and an invasiveness-promoting dedifferentiated 
state (Bailey et al., 2012; Knappe et al., 2016). Furthermore, the expression and 
activity of the master regulator of melanocyte development MITF potentially 
regulates melanoma cell plasticity (Vachtenheim and Ondrusova, 2015). 
Although MITF is recurrently amplified and was originally identified as a 
melanoma oncogene (Garraway et al., 2005), subsequent studies have indicated 
a more complex role of MITF in melanoma. MITF potentially follows a rheostat 
model, wherein different levels of MITF activity can have distinct effects on 
melanoma cells: (1) a very high MITF level leads to terminal differentiation 
followed by cell cycle exit and cell death, (2) a high MITF level promotes 
proliferation, (3) a low MITF level promotes invasion and inhibits proliferation, 
and (4) a very low MITF level results in senescence (Goding, 2011; Golan et al., 
2015; Riesenberg et al., 2015). MITF is strongly regulated by microenvironmental 
and intrinsic signals at transcriptional, translational, and posttranslational levels 
(Dar et al., 2016; Feige et al., 2011; Hartman et al., 2015; Lauss et al., 2015; 
Shah et al., 2010; Zhao et al., 2011). These regulation levels enable MITF levels 
to remain highly dynamic within melanomas, which majorly contributes toward 
tumor cell differentiation and plasticity in melanomas. 
Although the aforementioned studies indicated the importance of 
developmental programs in melanoma progression, these fundamental 
mechanisms have not been understood completely. First, the stage in which the 
developmental programs are turned on in melanomas remains unclear. Although 
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several studies have indicated the role of NC identities in advanced melanomas, 
a recent study using a zebrafish model indicated their earlier role in melanoma 
initiation (Kaufman et al., 2016); furthermore, several NC factors appear to be 
essential for tumor cell survival and therefore could be essential for early 
transformation. Second, whether the expression of different NC factors is 
regulated independently or a global change in the identity of these melanoma 
cells regulates the expression of these NC factors remains unclear. Although 
melanomas have a global NC identity, the factors regulating this identity remain 
unknown. Finally, no study has correlated NC identities to the clinical 
characteristics of patients with melanoma. 
 
Bone Morphogenic Protein Signaling Pathway 
Overview 
 Bone morphogenic proteins (BMPs) belong to the transforming growth 
factor β (TGF-β) superfamily and were originally identified as factors that induce 
bone formation (Urist, 1965). Subsequent studies indicated a broad range of 
roles of BMP signaling in regulating processes, such as differentiation, 
proliferation, angiogenesis, and apoptosis (Hemmati-Brivanlou and Thomsen, 
1995; Kobayashi et al., 2005; Mitchell et al., 2010; Stewart et al., 2010; Zou and 
Niswander, 1996), during development and in mature adult tissues. 
Dysregulation of this pathway is involved in genesis and progression of several 
disorders, including cancer. 
  
10 
BMP signaling involves ligand–receptor binding at the cell surface 
followed by the activation of the SMAD transcriptional cascade to regulate gene 
expression (Figure 1.3). BMP ligands are synthesized as large inactive precursor 
proteins. These contain two cleavage sites, R-X-K-R and R-X-X-R, which are 
cleaved by furin and procollagen C-proteinases, respectively, to yield mature 
BMP monomers (Cui et al., 2001). These monomers form homodimers or 
heterodimers with other BMP monomers through a cysteine disulfide bond to 
produce biologically active BMP ligands. These ligands are secreted outside the 
cell, where they bind to and activate the BMP receptor complex. In the absence 
of the ligand, two type I and two type II BMP receptors are present as 
independent homodimers on the cell surface (Rosenzweig et al., 1995). The 
presence of the ligand signals the receptors to assemble into a tetraheteromeric 
complex. Following the complex formation, the constitutively active type II 
receptor phosphorylates and activates the kinase domain of the type I receptor. 
The type I BMP receptor then phosphorylates the receptor SMADs (SMAD1, 
SMAD5, and SMAD8), enabling their release from the membrane. This 
phosphorylated SMAD1/5/8 complex then binds to SMAD4 and translocates to 
the nucleus to promote or repress expression of downstream genes. In addition 
to the aforementioned canonical pathway, BMPs can also independently regulate 
noncanonical pathways, such as the MAPK, phopshoinositide 3-kinase, and c-
Jun amino-terminal kinase pathways (Derynck and Zhang, 2003). 
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Figure 1.3: BMP signaling pathway 
Upon binding of the BMP ligand, the type II BMP receptor forms a complex with 
the type I BMP receptor, phosphorylates and actvates its kinase domain. The 
type I BMP receptor then phosphorylates and activates SMAD1/5/8 (Receptor 
SMADs or R-SMADs). Activated R-SMADs bind SMAD4 and translocate to the 
nucleus. Within the nucleus, these SMADs bind other nuclear factors and 
regulate transcipritional activation or repression of genes.  
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BMP signaling is regulated at multiple levels, thus aiding this pathway in 
regulating a broad spectrum of biological activities. First, the large number of 
BMP ligands and receptors provides the first layer of pathway regulation. 
Approximately 20 BMP ligands, 4 type I BMP receptors, and 3 type II BMP 
receptors have been identified in mammals. Different homodimeric or 
heterodimeric BMP ligand complexes have varying affinities toward different 
BMP receptor complexes. Although some of these complexes act redundantly, 
distinct spatial and temporal expression of their ligands and receptors facilitates 
pathway regulation in a physiological setting. Second, the factors that negatively 
regulate this pathway provide a secondary layer of regulation. BMP pathway 
antagonists, such as chordin, noggin, and follistatin, are secreted, factors which 
bind to BMP ligands and block their binding to BMP receptors, thereby negatively 
regulating BMP signaling (Groppe et al., 2002; Harrington et al., 2006; Zhang et 
al., 2008). The BMP pathway is also intrinsically regulated as a part of a negative 
feedback loop by inhibitory SMADs (SMAD6 and SMAD7), which act by 
competing with SMAD1 to bind to BMP receptors (Hanyu et al., 2001; Ishida et 
al., 2000). Finally, the specificity of BMP pathway targets, achieved at a 
transcriptional level, provides an additional level of regulation. Depending on 
cofactor expression, the SMAD1/5/8 transcriptional complex can positively or 
negatively regulate the expression of different sets of genes in different cell types 
(Morikawa et al., 2013). 
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Genome-wide mapping studies using phosphoSMAD1/5/8 antibodies and 
ChIPseq or promoter arrays have identified several BMP target genes. These 
studies have been performed on different cell types, such as endothelial, 
embryonic fibroblast, pulmonary arterial smooth muscle, hair follicle stem, and 
embryonic stem cells (Genander et al., 2014; Kaneda et al., 2011; Morikawa et 
al., 2011), and have revealed the following: (1) The SMAD1 binding motif is 
somewhat unique in different tissues. (2) Although genes such as ID1, ID2, ID3, 
and SMAD6 are canonical BMP targets found in all cell types, cell type-specific 
BMP target genes are also present, potentially because context-dependent 
cofactor-binding. (3) BMP-SMAD1 can transcriptionally activate or repress gene 
expression. 
 
BMP Signaling in Cancer (Including Melanoma) 
 Although BMP signaling has been implicated in many cancers, 
understanding its precise role in tumorigenesis has been difficult because of the 
complexity of the pathway and its functional diversity. This has also hindered the 
use of BMP pathway modulators for therapeutic purposes. However, several 
recent studies have identified specific roles of the BMP pathway in tumorigenesis 
(Table 1.1). These studies have indicated a bidirectional role of BMP signaling in 
tumorigenesis. BMP signaling activity can either promote or inhibit tumorigenesis: 
depending on the ligand–receptor complex combination, cancer type, and  
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Cancer BMP pathway 
components 
Role Function of BMP 
pathway 
Reference 
Colorectal 
cancer 
BMPRII, 
SMAD4, BMP2 
Tumor 
suppressive 
Anti-proliferation (Hardwick et 
al., 2004; 
Kodach et al., 
2008) 
Colorectal 
cancer 
BMP4, BMP7 
(SMAD4-
independent 
role) 
Tumor 
promoting 
Pro-invasion 
(Promotes EMT) 
(Deng H, 2007; 
Grijelmo C, 
2007) 
Gastric 
carcinoma 
BMP2, BMP4 Tumor 
suppressive 
Anti-proliferation (Shirai et al., 
2011) 
Prostrate 
cancer 
BMP7 Tumor 
suppressive 
Anti-proliferation (Miyazaki et al., 
2004) 
Glioblastoma BMP4, 
BMPR1B 
Tumor 
suppressive 
Promotes 
terminal 
differentiation of 
cancer stem cells 
(CSC) 
(Lee et al., 
2008; Piccirillo 
et al., 2006) 
Heptacellular 
carcinoma 
BMP4 Tumor 
suppressive/ 
Tumor 
promoting 
Promotes 
terminal 
differentiation of 
CSCs at high 
levels 
Inhibits terminal 
differentiation of 
CSCs at low 
levels 
(Zhang et al., 
2012) 
Pancreatic 
tumors, 
Melanoma 
BMP9/ALK1 Tumor 
promoting 
Promotes 
angiogenesis 
(Cunha et al., 
2010; Hu-Lowe 
et al., 2011) 
Breast cancer BMP2, BMP7, 
BMPR1B 
Tumor 
promoting 
Promotes 
metastasis 
(Alarmo et al., 
2008; Helms et 
al., 2005; 
Katsuno et al., 
2008) 
Breast cancer BMP7, Noggin 
(BMP pathway 
antagonist) 
Tumor 
suppressive 
Inhibits 
metastasis 
(Buijs et al., 
2007; 
Tarragona et 
al., 2012) 
 
Table 1.1: Bidirectional roles and diverse functions of BMP pathway during 
cancer progression   
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tumorigenesis stage, BMPs can regulate diverse biological functions to promote 
or inhibit tumorigenesis. Thus, the BMP pathway is pleiotropic in tumors.   
The role of BMP signaling in melanomagenesis remains unclear. Cell line-
based studies have reported distinct and somewhat contradicting roles of BMP 
factors in melanomagenesis. Studies from the Rothhammer lab have 
demonstrated that the BMP ligands BMP4 and BMP7 are overexpressed in 
melanomas (Rothhammer et al., 2005). BMP7 can either promote or inhibit cell 
migration in different melanoma cell lines (Hsu et al., 2008; Rothhammer et al., 
2005). Independent studies have also found the role of a known BMP target, 
DIDO1, in promoting melanoma cell survival (Braig and Bosserhoff, 2013). 
Although these cell-based in vitro studies have implicated the role of BMP 
signaling in melanomas, cellular consequences caused by BMP signaling and 
the downstream targets of this pathway in melanomas is largely unknown. This is 
partly because genome-wide ChIP studies on phosphoSMAD1/5/8 in melanoma 
cells and studies on the role of BMP signaling in an in vivo model of melanoma 
are scant. Notably, no genome-wide mapping studies has reported 
phosphoSMAD1/5/8 in any cancer, thus indicating the need to further exploit the 
role of BMP signaling in tumorigenesis. 
 
BMP Signaling in NC and During Melanocyte Development 
BMP signaling has been implicated in several aspects of NC development. 
First, functional and genetic studies in avian, zebrafish, and Xenopus models 
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have reported critical roles of BMP signaling in (1) inducing NC (Liem et al., 
1995; Marchant et al., 1998; Mayor et al., 1997; Nguyen et al., 1998; Ragland 
and Raible, 2004); (2) delaminating NC, by regulating EMT to enable cells to 
migrate and populate different parts of the embryo (Coles et al., 2004; Sela-
Donenfeld and Kalcheim, 1999, 2000); (3) regulating cell death, to maintain 
appropriate tissue morphogenesis and patterning (Ellies et al., 2002; Graham et 
al., 1994; Marazzi et al., 1997); and (d) specifying NC fate (Reissmann et al., 
1996; Shah et al., 1996). 
The BMP and Wnt signaling pathways act antagonistically in NC during 
fate specification and differentiation of neurons and melanocytes. Studies in 
zebrafish and avian systems have indicated that NC fate specification occurs in a 
progressive manner, where multipotent NC cells are initially fate-restricted to 
generate neurons and later to generate melanocytes (Bronner-Fraser M, 1988; 
Raible and Eisen, 1994). BMP and Wnt signaling governs lineage segregation of 
neurons and melanocytes, respectively (Dorsky et al., 1998; Jin et al., 2001; 
Reissmann et al., 1996; Shah et al., 1996). BMP receptors and ligands are 
present in NC and adjacent tissues, respectively, during neuronal fate 
specification (McPherson et al., 2000; Schneider et al., 1999). Their expression is 
progressively downregulated; this downregulation spatially and temporally 
overlaps with Wnt-induced melanocyte fate specification (Jin et al., 2001). 
Concurrently, the induction of BMP signaling in cultured quail NC cells can 
promote neuronal differentiation at the expense of melanocytes (Jin et al., 2001). 
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Taken together, these studies have indicated that BMP signaling is important for 
neuronal fate specification; however, it can also inhibit Wnt signaling-induced 
melanocyte differentiation at least in vitro. 
 
GDF6/BMP13 
 GDF6 (also called BMP13) is a BMP pathway ligand, with sequence 
similarity with other BMP ligands (Chang et al., 1994; Storm et al., 1994). GDF6 
has 20%–30% amino acid homology with TGF-β and 40%–60% homology with 
other BMP ligands (Williams et al., 2008). The closest family members of GDF6 
are GDF5 and GDF7, with 80%–90% amino acid homology with each other. 
Because of this high homology, these factors may act redundantly. Although 
several BMP ligands have orthologs in invertebrate species, such as Drosophila, 
GDF6 appears to be vertebrate-specific (Ducy and Karsenty, 2000). 
 Although the GDF6 structure requires further elucidation, cell-based 
studies have demonstrated that GDF6 can activate both canonical and 
noncanonical BMP signaling. Because of its sequence similarity with other BMP 
ligands, GDF6 potentially undergoes processing similar to that other BMP ligands 
do, to form a bioactive cytokine. In vitro, the bioactive GDF6 unit forms either a 
homodimer or a heterodimer with BMP2 and BMP4, when expressed in the same 
cell (Chang and Hemmati-Brivanlou, 1999); however, the in vivo mechanism of 
the dimer formation has not been reported thus far. Similar to most BMP ligands, 
GDF6 binds to BMPR2 and can activate BMPR1A (ALK3) in chondrocytes 
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(Wang et al., 2013b) and BMPR1B (ALK6) in pluripotent mesenchymal cells 
(Erlacher et al., 1998), followed by the activation of the canonical SMAD1/58 axis 
of BMP signaling (Hanel and Hensey, 2006; Pant et al., 2013; Wang et al., 
2013b). GDF6-driven BMP receptor activation can also activate the noncanonical 
p38 MAPK pathway (Pant et al., 2013; Wang et al., 2013b) to enable a different 
set of functions. Because of the lack of genome-wide mapping studies on the 
aforementioned transcription factors, the transcriptional targets of GDF6-induced 
BMP signaling remain unknown. 
The expression and function of GDF6 were primarily identified in the adult 
cartilaginous tissues; however, its expression was low or absent in other tissues, 
such as intestinal, muscular, and placental tissues (Chang et al., 1994). 
Nevertheless, subsequent studies identified GDF6 expression in several 
structural tissues, such as connective, tendon, and ligament tissues, during bone 
repair and healing (Chuen et al., 2004; Wong et al., 2005). Several in vitro 
studies on the role of GDF6 in adult tissues have indicated that it can induce the 
expression of structural extracellular matrix proteins, such as collagen and 
proteoglycan, during bone repair and healing (Li et al., 2003; Nochi et al., 2004; 
Yeh et al., 2004). Therefore, GDF6 most probably acts as a factor that provides 
structural support during tendon repair. 
As mentioned, GDF6 expression was initially identified only in adult 
tissues; subsequently, the expression and roles of GDF6 homologs were also 
noted during embryogenesis. In zebrafish, during the earliest expression of 
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GDF6, its ortholog gdf6a or radar is expressed as a maternal protein (Goutel et 
al., 2000). At this stage, gdf6a/radar regulates dorsoventral patterning of the 
embryo: its loss leads to a dorsalized phenotype, whereas its overexpression 
results in a ventralized phenotype. In zebrafish, Xenopus, and mice, GDF6 
orthologs have also been implicated in retinal development; their loss leads to 
increased cell death in the developing retina, thus reducing the eye size (Asai-
Coakwell et al., 2009; Gosse and Baier, 2009; Hanel and Hensey, 2006; Pant et 
al., 2013). Consistent with this, the GDF6 locus of patients with coloboma, a 
disease that causes ocular abnormalities, carries a recurrent deletion (Asai-
Coakwell et al., 2007; Gonzalez-Rodriguez et al., 2010). GDF6 also regulates the 
differentiation of mesenchymal progenitors during skeletal development 
(Clendenning and Mortlock, 2012). Mice with complete loss of gdf6 demonstrate 
incomplete skull joint development and bone fusion in the wrists and ankles, 
because of precocious differentiation (Asai-Coakwell et al., 2009; Settle et al., 
2003). Mice with a loss-of-function mutation in gdf5 and gdf6 demonstrate more 
pronounced skeletal defects and do not progress to adulthood (Settle et al., 
2003). Consistent with this, Klippel-Feil syndrome, a disorder associated with 
skeletal defects in humans, is frequently associated with GDF6 mutations 
(Tassabehji et al., 2008). Taken together, these findings indicate that GDF6 is 
pleiotropic with functions, including providing mechanical support to tissues, 
promoting cell survival, and regulating differentiation. 
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Zebrafish Model for Melanoma 
Overview 
Biological and biomedical research using small animal models, such as 
the zebrafish model, has revealed crucial results. The animal models represent 
miniature systems to study fundamental biological processes in a physiological 
context, thereby closing the gap between high-throughput in vitro cell-based 
systems and low-throughput mouse model systems. These models also have 
unique attributes, such as ex vivo development at rapid rates, high fecundity, and 
visual accessibility because of the transparency of embryos. These features have 
facilitated researchers in elucidating several developmental and disease-related 
processes. 
 The use of zebrafish to model cancers and study aspects of tumor biology 
has increased considerably. Among the several modeled cancers, substantial 
work has been focused on melanoma research, partly because these models 
have been exploited for studying NC and melanocyte development. Several 
genetically engineered melanoma models have been created in zebrafish. In 
2005, Patton et al. created the first genetic model of melanoma in zebrafish. The 
authors coupled melanocyte-specific expression of human mutant BRAF 
(BRAFV600E) along with loss-of-function P53 to induce melanoma initiation. In 
subsequent studies, additional melanoma models were created by using other 
commonly altered melanoma genes, such as NRAS and HRAS (Dovey et al., 
2009; Santoriello et al., 2010). Melanomas arising in these zebrafish models 
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grow outwards and therefore are easy to visualize, dissect, and analyze (Figure 
1.4). Histological analysis of melanomas arising in zebrafish had pathological 
characteristics similar to human melanomas (Dovey et al., 2009; Patton et al., 
2005; Santoriello et al., 2010). 
Transgenic tools have also been created using zebrafish to study the 
effect of potential cancer genes on melanoma progression (Ceol et al., 2011) 
(Figure 1.5). This approach uses two key components: (1) 
Tg(Pmitfa:BRAFV600E);p53(lf);mitfa(lf) zebrafish, which lacks melanocytes 
because of a loss-of-function mutation in mitfa, and (2) the miniCoopR vector, 
which harbors both a wild-type copy of mitfa and an adjacent cassette into which 
a potential gene of interest could be recombined and expressed under the mitfa 
promoter. After the injection of a miniCoopR plasmid into 
Tg(Pmitfa:BRAFV600E);p53(lf):mitfa(lf) zebrafish embryos, wild-type mitfa 
enables reconstitution of melanocytes, which also express the recombined gene 
of interest. Because of the genetic background, reconstituted melanocytes also 
express the tumor-promoting BRAFV600E oncogene, become p53 mutant, and 
have the propensity to develop into melanomas. If the gene of interest has tumor-
promoting properties, it may further accelerate the melanoma onset. Owing to the 
high fecundity of zebrafish, the aforementioned approach was originally used to 
screen large numbers of genes for their oncogenic role in melanoma progression 
(Iyengar et al., 2012). Subsequently, this approach was adapted with Crispr- 
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Figure 1.4: A zebrafish model of melanoma 
Zebrafish with melanocyte-specific expression of BRAFV600E and loss of 
function P53 develop externally visible melanomas.   
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Figure 1.5: miniCoopR assay 
Injection of the miniCoopR vector, which contains a mitfa ORF and a candidate 
gene of interest, into embryos of mitfa loss of function zebrafish that lack 
melanocytes causes a chimeric rescue of melanocytes, and these melanocytes 
also express the candidate gene. Zebrafish with rescued melanocytes are 
monitored into adulthood and scored for melanoma onset, and the potential of a 
gene to accelerate melanoma onset as compared to a control like EGFP is 
measured.   
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Cas9 targeting to knockout candidate tumor suppressors and test for accelerated 
tumor onset (Ablain et al., 2015). 
 
Zebrafish Melanoma Genome 
The zebrafish melanoma genome has been explored to determine the use 
of cross-species comparative oncogenomics for identifying commonly altered 
drivers. Yen et al. (2013) performed exome sequencing of BRAFV600E and 
NRASQ61K mutant zebrafish melanomas to define DNA base substitutions and 
recurrent CNVs. DNA base substitution analysis revealed a low mutational 
burden, unlike human melanomas. Furthermore, mutational analysis indicated a 
low number of recurrently mutated genes, suggesting that these mechanisms 
may not considerably contribute to tumor progression. However, zebrafish 
melanomas, similar to their human counterparts, displayed widespread CNVs. 
Moreover, the orthologs of human PRKACA and TERT—both of which are 
known melanoma drivers—were amplified in zebrafish melanomas. These 
studies suggest that zebrafish melanomas may be primarily driven by CNVs. The 
results of comparative genomic analysis with human and zebrafish melanomas 
for ascertaining common genes with CNVs may facilitate the identification of 
novel cancer drivers. 
 
Examining Role of Developmental Mechanisms in Melanoma Using Zebrafish 
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Signaling mechanisms involved in melanocyte differentiation are often 
dysregulated in melanomas, and the zebrafish model has helped gain insight into 
these mechanisms. As described previously, the role of MITF in melanomas is 
complex; MITF promotes proliferation at high levels, whereas at low levels, it 
promotes invasion (Goding, 2011; Golan et al., 2015; Riesenberg et al., 2015). 
This multifaceted role of MITF has been studied in the zebrafish model during 
melanocyte development and in melanoma progression. Taylor and colleagues 
(2011) used a hypomorphic, conditional mitfa, an ortholog of human MITF, to 
show that low mitfa activity, which was not endogenous, enables the division of 
terminally differentiated melanocytes. Corroborating these results in the 
melanoma context, Lister and colleagues (2014) reported that low mitfa activity 
elevated the oncogenic potential of melanocytes in zebrafish. The authors 
coupled melanocyte-specific gain-of-function BRAFV600E expression with the 
hypomorphic mitfa allele and reported that low nonendogenous mitfa activity can 
initiate tumors and that complete loss of mitfa from an established melanoma 
leads to tumor regression; thus, MITF is a lineage-addiction oncogene, the 
expression of which is regulated at a moderate level in melanomas. In addition to 
MITF, SOX10 and SOX9 are transcription factors that form the core gene 
regulatory network, which orchestrates melanocyte differentiation (Greenhill et 
al., 2011). By using mathematical modeling and through experimental 
observations in zebrafish, Greenhill and colleagues (2011) reported that (1) 
SOX10 represses MITF-dependent activation of melanocyte lineage genes and 
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(2) SOX9 activates melanocyte lineage genes in a MITF-independent manner. 
Notably, in melanomas, SOX10 and SOX9 antagonistically crossregulate each 
other (Shakhova et al., 2015). SOX10 is essential for melanoma cell survival; 
SOX10 loss results in SOX9 upregulation, leading to cell cycle arrest and death. 
Taken together, these findings indicate that the gene regulatory network involved 
in melanocyte differentiation is critical for melanoma cell growth and survival. 
The study of melanomas using zebrafish models has revealed newer roles 
of NC identities in the early stages of melanomagenesis. Kauffman and 
colleagues (2016) used zebrafish melanoma to probe NC identities; the authors 
noted that these identities are invoked in the early stages of tumorigenesis. The 
authors engineered transgenic zebrafish that expressed EGFP under the 
promoter of an NC-specific retroelement, crestin. In these fish, EGFP expression 
was specifically observed in the NC, and this expression was turned off in 
differentiated melanocytes. When the promoter was introduced in a tumor-prone 
zebrafish strain, these reporter fish revealed EGFP expression only in 
melanocytes, which ultimately developed into tumors. These data indicated a fate 
change toward a more NC state during tumor initiation. Forced activation of this 
state, by using melanocyte-specific overexpression of the NC sox10, accelerated 
melanoma onset. In fish and human melanoma cells, the authors reported 
epigenetic changes that activated several NC factors, indicating a genome-level 
change in melanomas toward an NC state. 
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RATIONALE AND OBJECTIVES 
 
Melanomas have widespread CNVs; differentiating driver genes among 
linked passenger genes within a region of recurrent CNVs is difficult. Here we 
plan to address this issue of identifying drivers amongst passengers by taking 
advantage of synteny. Evolution of the genome has caused a great degree of 
genome reorganization between species. Species whose evolutionary distance is 
more have more extensive genome reorganization. Because humans and 
zebrafish have an evolutionary distance of approximately 400 million years, their 
genome organization is very distinct. While a driver is physically linked to a set of 
passengers within a CNV region of human melanomas, the ortholog of that driver 
will most likely be linked to a different set of passengers in zebrafish melanomas. 
Therefore, I predict that comparative copy number analysis to identify genes 
commonly amplified or deleted in melanoma of both species should be enriched 
for driver genes. By using this approach, I plan to identify novel melanoma 
genes, which recurrently undergo CNVs. Through this approach of comparative 
genomics, I identify a novel melanoma oncogene, GDF6 and study its functional 
and mechanistic role in melanoma progression as well as the clinical relevance 
of its expression in patients with melanoma. 
Melanomas can invoke NC identities; however, no study has reported the 
clinical relevance of these identities in patients with melanoma. Here, I use 
transcriptome analysis in a zebrafish model of melanoma to identify the NC gene 
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signature. I further identify the clinical relevance of this signature in patients with 
melanoma. 
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CHAPTER II 
Ligand-activated BMP signaling inhibits cell differentiation and death to 
promote melanoma 
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ABSTRACT 
Oncogenomic studies have revealed copy number variations (CNVs) that alter 
genes involved in tumor progression, but identifying such genes has been difficult 
because they are often contained in large chromosomal intervals amongst 
several bystander genes. To address this problem and identify new oncogenes, 
we performed comparative oncogenomics of human and zebrafish melanomas 
and found the BMP ligand GDF6. GDF6-induced BMP signaling maintains a 
trunk neural crest gene signature in melanomas. In maintaining this signature, 
GDF6 represses the melanocyte differentiation gene MITF and the proapoptotic 
factor SOX9, allowing melanoma cells to remain undifferentiated and survive. 
GDF6 is specifically expressed in melanomas and not melanocytes, and its 
expression level in melanomas inversely correlates with patient survival. Our 
study uncovers a fundamental role for GDF6 and BMP signaling in governing an 
embryonic cell gene signature to promote melanoma progression and provides 
new opportunities for targeted therapy of GDF6-positive cancers. 
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Introduction 
The identification of new cancer-promoting genes has yielded mechanistic 
insights into tumor progression and led to the development of several targeted 
therapies. In cutaneous melanoma, the finding of common BRAF mutations 
highlighted the importance of ERK pathway activation in tumor initiation and 
maintenance. These studies also triggered the design of vemurafenib and other 
MAPK pathway inhibitors, which were the first drugs to extend survival of patients 
with advanced disease (Bollag et al., 2010; Chapman et al., 2011; Davies et al., 
2002; Larkin et al., 2014). Immunotherapies, such as the CTLA4 inhibitor 
Ipilimumab and the PD1 inhibitors Nivolumab and Pembrolizumab (Atkins and 
Larkin, 2016; Leach et al., 1996), have also had a major impact on melanoma 
therapy as they have dramatically improved the long-term survival rates of 
advanced-stage patients (Eggermont et al., 2016; Robert et al., 2015b). Despite 
this progress, many patients do not respond to certain therapies whereas others 
suffer from drug toxicity, therapy resistance or disease relapse (Robert et al., 
2015a; Su et al., 2012; Weber et al., 2012), underscoring a need to identify 
additional targets for therapeutic intervention.  
Along with identifying BRAF and other recurrently mutated cancer genes, 
sequencing strategies have also defined genomic intervals subject to recurrent 
copy number variation (CNVs). However, cancer-promoting genes in CNVs have 
been difficult to identify because: 1) they are often not affected by point mutations 
and 2) are typically present in large CNVs alongside several bystander genes 
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that have no effect on tumor progression. Analysis of CNVs has the potential to 
uncover several new cancer-promoting genes in solid tumors such as melanoma, 
in which a large percentage of the genome is subject to recurrent CNV (Hodis et 
al., 2012). 
Oncogenomic studies have also revealed expression profiles that reflect 
broad changes in cellular identity that distinguish cancer cells from normal tissue 
(Roy and Hebrok, 2015). In many cancers, tumor cells adopt cellular and 
molecular identities that overlap with their lineally-related embryonic cells. 
Adopting these identities can endow tumor cells with properties, such as the 
ability to proliferate or migrate, not found in their differentiated counterparts 
(Daley, 2008; Hendrix et al., 2007; Maguire et al., 2015). Reawakening of neural 
crest character in nascent melanomas, as exemplified by expression of neural 
crest specification factors SNAI2 (SLUG) and BRN3A (POU4F1) has been 
shown to enable pro-tumorigenic properties like migration and survival, 
respectively (Gupta et al., 2005; Hohenauer et al., 2013). Subsequent studies 
have noted additional gene expression and functional relationships between 
melanoma and neural crest cells (Shakhova, 2014; White et al., 2011). Whereas 
similarities between tumor and embryonic cells in melanomas and other cancers 
have been recognized, the factors that establish and maintain an embryonic 
identity in tumor cells are poorly understood. Specifically, it is not clear whether 
embryonic genes are regulated separately to reconstitute an embryonic identity 
or whether a programmatic change that simultaneously regulates many genes is 
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involved. In addition, the consequences of abrogating embryonic identity in 
melanoma and other cancers have not been thoroughly investigated. 
In this study we report the identification of the GDF6 oncogene, a BMP 
factor that is recurrently amplified and specifically expressed in melanomas. 
GDF6, which is expressed in the embryonic neural crest, regulates a trunk neural 
crest gene signature in melanomas.  Loss of GDF6 results in differentiation and 
death of melanoma cells, indicating that GDF6 and the BMP signaling pathway 
are required for tumor maintenance and are thus potentially important targets in 
melanoma therapy.  
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Results 
Comparative oncogenomics and expression analyses identify GDF6 
dysregulation in melanoma 
We hypothesized that a cross-species comparative approach with 
zebrafish would aid in identification of cancer genes in regions of broad CNVs. 
Humans and zebrafish are diverged by 420 million years (Postlethwait et al., 
1999), and the genomic reorganization that has occurred over time is predicted 
to frequently place orthologous driver genes next to different neighboring genes 
in each species. Consequently, orthologous driver genes would be altered in 
both species, but changes to neighboring passenger genes would be limited to a 
single species. To test this hypothesis, we sought to compare genes that are 
recurrently amplified in human melanomas, roughly 10% of the genome 
(Beroukhim et al., 2010), to genes recurrently amplified in zebrafish melanomas. 
Using melanomas that arose autochthonously in a Tg(mitfa:BRAFV600E); p53(lf) 
zebrafish strain (Patton et al., 2005), we performed array comparative genomic 
hybridization (aCGH) to generate CNV profiles (Figure 2.1). The 
Tg(mitfa:BRAFV600E); p53(lf) strain combines a transgene that drives 
expression of human BRAFV600E in the melanocyte lineage with a p53 loss-of-
function mutation, and every animal of this genotype ultimately develops one or 
more melanomas. aCGH values were analyzed with the JISTIC algorithm 
(Sanchez-Garcia et al., 2010) to define recurrently varied intervals, which largely 
overlapped with intervals obtained in an independent study of zebrafish  
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Figure 2.1: GDF6 is recurrently amplified and specifically expressed in 
melanomas 
(A) Circos plot displaying gene copy number gains and losses of zebrafish 
melanomas across 25 chromosomes. JISTIC G-scores are displayed as pale red 
shading (amplifications (min=0; max=1550)) and blue shading (deletions (min=0; 
max=2150)). –log10-transformed JISTIC Q-values with a cut-off of 0.6 
(corresponding to an untransformed Q-value of 0.25) are displayed as bold red 
lines (amplifications (min=0; max=11)) and bold blue (deletions (min=0; 
max=11)). Dotted circles represent –log10-transformed Q-value of 0 (center) and 
11 (outer: amplification; inner: deletion). (B) Venn diagram of orthologous genes 
significantly amplified in human and zebrafish melanomas from a total of 10380 
human-zebrafish gene pairs (hypergeometric test, P-value: 2.0e-15) (C) Genes 
significantly upregulated in zebrafish melanomas as compared to melanocytes 
(microarray dataset) are plotted in order of their fold change. Only genes with fold 
change > 2 and adjusted p-value <0.05 are plotted. Recurrently amplified genes 
with amplified human orthologs are indicated (red). gdf6b (big red dot) and gdf6a 
(big black dot) are indicated. Dashed horizontal line represents a fold change of 
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2. (D) Immunostaining of Tg(mitfa:BRAF(V600E));p53(lf) zebrafish scales bearing 
melanoma cells (top) or normal melanocytes (bottom). DAPI (blue), Gdf6b 
(green), Mitfa (red), and a merged image of all channels are shown. Mitfa 
antibody specificity is shown in Figure 2.3. Scale bar, 10 µm. 
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melanomas (Yen et al., 2013). Recurrently amplified genes from JISTIC intervals 
were compared to their human orthologs. The degree of overlap between 
orthologs amplified in both species (374 genes) is greater than would be 
expected by chance (247 genes) (Figure 2.1), suggesting that amplification of 
similar driver genes mechanistically underlies tumor formation in both species. 
As further indication of mechanistic conservation, known melanoma drivers were 
recurrently amplified in both species, including TERT, MYC and SETDB1 (Ceol 
et al., 2011; Kraehn et al., 2001; Pirker et al., 2003).  
Expression analyses were used to further winnow the list of candidates. 
Since copy-number-amplified driver genes predominantly act by upregulation of 
wild-type transcripts, we obtained transcriptional profiles of zebrafish melanomas 
and normal melanocytes. Briefly, unpigmented EGFP-positive melanocytes and 
melanoma cells were sorted from scales and tumors, respectively, of 
Tg(mitfa:BRAFV600E); p53(lf); Tg(mitfa:EGFP); alb(lf) fish. RNA was prepared 
from each cell population and subjected to both microarray analysis and 
massively parallel RNA sequencing (RNAseq). Genes recurrently amplified and 
transcriptionally upregulated in both species (120 genes; fold change >2, 
adjusted P-value < 0.05) included the BMP factor GDF6 (a.k.a. BMP13) and its 
zebrafish ortholog gdf6b (Figure 2.1, B and C and Figure 2.2, A-C). To determine 
if Gdf6b protein was similarly enriched in melanomas, we generated an antibody 
that specifically recognizes Gdf6b (Figure 2.3). Whereas Gdf6b protein was 
readily detected in tumor cells from Tg(mitfa:BRAFV600E);p53(lf) fish, we did not  
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Figure 2.2: GDF6 orthologs are amplified and upregulated in human and 
zebrafish melanomas  
(A) Heat map showing the human GDF6 locus across 111 human melanomas 
(left) and the zebrafish gdf6b locus across 38 zebrafish melanomas (right). Red 
indicates amplification, blue indicates deletion. (B) Log2-transformed fold change 
of gdf6a and gdf6b expression in zebrafish melanomas as compared to 
melanocytes as determined by qRT-PCR. (C) GDF6 transcript FPKM values from 
normal human melanocytes and melanomas. Two-tailed Welch’s t-test 
***P<0.001. 
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Figure 2.3: Specificity of zebrafish Gdf6b and Mitfa antibodies 
(A) Immunostaining with Gdf6b antibody (top) and pre-immune serum (bottom) in 
4-somite stage AB embryos. Expression of Gdf6b is seen in the neural plate 
(arrow head) as described previously (Bruneau and Rosa, 1997). Scale bars, 100 
µM. (B) Left, immunostaining with Mitfa antibody in wild-type AB zebrafish 
embryos. Right, immunostaining with Mitfa antibody in mitfa(lf) zebrafish 
embryos. Mitfa (top), DAPI (bottom). Scale bars, 100 µM. 
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detect Gdf6b in normal melanocytes from these same animals (Figure 2.1D). 
Human genes often have two zebrafish orthologs because of a partial genome 
duplication in the teleost lineage. The second zebrafish ortholog of human GDF6, 
gdf6a, was not recurrently amplified but was among the most transcriptionally 
upregulated genes in melanomas as compared to melanocytes (Figure 2.1C and 
Figure 2.2B). Together, these data highlight the recurrent amplification and 
tumor-specific expression of GDF6 genes in human and zebrafish melanomas.  
GDF6 orthologs were particularly interesting because their expression 
pattern in zebrafish embryos suggested they may regulate melanocyte 
development. Zebrafish orthologs of GDF6 are expressed during neurulation and 
development of the neural crest, the embryonic tissue that gives rise to 
melanocytes (Bruneau and Rosa, 1997; Reichert et al., 2013; Rissi et al., 1995). 
Using in situ hybridization we confirmed expression of gdf6a and gdf6b in the 
neural tube and the neural crest, respectively. Later in development, we found 
that their expression was absent from differentiating embryonic melanocytes 
(Figure 2.4). Factors involved in neurulation and neural crest signaling have been 
previously implicated in promoting melanoma progression (Gupta et al., 2005; 
Kaufman et al., 2016; Maguire et al., 2015), and we were intrigued by the notion 
that a developmental role for GDF6 genes could be reiterated to promote 
melanomagenesis. 
  
GDF6 modulation alters melanoma onset in zebrafish 
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Figure 2.4:  Expression of zebrafish GDF6 orthologs during embryonic 
development 
(A) In situ hybridization with gdf6a antisense probe showing expression of gdf6a 
in the neural crest at the 6-somite stage. A gdf6a sense probe was used as a 
negative control. Top, dorsal view. Bottom, lateral view. Scale bar, 100 µM (B) In 
situ hybridization with gdf6b antisense probe showing expression of gdf6b in the 
neural tube at the 6-somite stage. A gdf6b sense probe was used as a negative 
control. Top, dorsal view. Bottom, lateral view. Scale bar, 100 µM (C) In situ 
hybridization with gdf6a and gdf6b probes showing their lack of expression at the 
18-somite stage. In situ hybridization of mitfa shows  melanocyte specification at 
this stage. No gdf6a or gdf6b staining was found in developing melanocytes. 
Scale bar, 100 µM. 
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 To assess whether GDF6 genes could promote melanoma, we first 
examined how their elevated expression affected tumor onset in zebrafish. We 
expressed gdf6a and gdf6b in the melanocyte lineage of Tg(mitfa:BRAFV600E); 
p53(lf); mitfa(lf) zebrafish using the miniCoopR system, as previously described 
(Ceol et al., 2011). The mitfa(lf) mutation prevents melanocyte development and 
melanoma formation in Tg(mitfa:BRAFV600E); p53(lf) fish. When single-cell 
embryos from the Tg(mitfa:BRAFV600E); p53(lf); mitfa(lf) strain were injected 
with miniCoopR-EGFP, 21% of these animals later developed chimeric rescue of 
melanocytes. However, in embryos injected with miniCoopR-gdf6a or 
miniCoopR-gdf6b, only 0.6% and 7% of injected animals had melanocyte rescue, 
respectively (Figure 2.5A). This lack of melanocyte rescue was not observed in 
control embryos that were injected with miniCoopR vectors that had premature 
stop codons engineered into the gdf6 genes (Figure 2.5A). In addition to the low 
percentages of miniCoopR-gdf6a or miniCoopR-gdf6b-injected embryos that 
showed melanocyte rescue, the embryos that were rescued had significantly 
lower numbers of melanocytes (Figure 2.5B). Because of this poor rescue we 
were only able to perform melanomagenesis assays with miniCoopR-gdf6a-
injected animals. When allowed to develop to adulthood, fish with melanocyte-
driven gdf6b expression had accelerated melanoma onset (median onset = 13 
weeks) as compared to EGFP-expressing controls (median onset = 17 weeks) 
(Figure 2.6A). Accelerated onset was dependent on BRAFV600E and loss of  
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Figure 2.5: Effects of zebrafish GDF6 orthologs on melanocyte numbers 
(A) Quantification of the fraction of zebrafish embryos with melanocyte rescue 
following injection of indicated miniCoopR constructs in 
Tg(mitfa:BRAFV600E);p53(lf);mitfa(lf) zebrafish. gdf6a** and gdf6b** are forms of 
gdf6a and gdf6b with premature stop codons, respectively. Error bars indicate 
s.e.m.: n=3 independent experiments. (B) Quantification of the number of 
melanocytes per rescued embryo. Error bars indicate s.e.m.: n=10 embryos. (C) 
Representative images of Tg(mitfa:BRAFV600E);p53(lf);gdf6a(lf)/+ and 
Tg(mitfa:BRAFV600E);p53(lf);gdf6a(lf) zebrafish. Boxed region from the top 
panel is shown in the bottom panel. Two-tailed Student’s t-test, *P< 0.05, **P< 
0.01, ***P< 0.001, ns, not significant.  
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Figure 2.6: GDF6 modulation alters melanoma growth 
(A) Melanoma-free survival curves for 
Tg(mitfa:BRAFV600E);p53(lf);mitfa(lf) zebrafish injected with miniCoopR-
gdf6b or miniCoopR-EGFP. Statistical analysis was performed with a Wilcoxon 
rank sum test. (B) Melanoma-free survival curves for 
Tg(mitfa:BRAFV600E);p53(lf) and 
Tg(mitfa:BRAFV600E);p53(lf);gdf6a(lf) zebrafish. Statistical analysis was 
performed with a Wilcoxon rank sum test. (C) Immunoblot showing expression 
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and quantification of GDF6 protein levels (relative to GDF6 protein in A375 
melanoma cells) in melanoma cell lines. Loading control used was GAPDH. 
Copy number values of the GDF6 locus in the different melanoma cell lines 
obtained from the COSMIC database are shown. (D) Immunoblots showing 
expression of GDF6 and GAPDH in A375 melanoma cells (top) and M14 
melanoma cells (bottom) overexpressing GDF6. (E) Left, tumor formation in mice 
injected with A375 cells (1x106 cells injected per mouse) overexpressing GDF6 or 
empty vector control. Error bars indicate s.e.m.; n=3. Right, tumor formation in 
mice injected with M14 cells (1x106 cells injected per mouse) overexpressing 
GDF6 or empty vector control. Error bars indicate s.e.m.; n=3. (F) Top, 
immunoblots showing expression of GDF6 in A375 melanoma cells expressing 
an shRNA targeting EGFP or two independent GDF6-targeted shRNAs. Bottom, 
immunoblots showing expression of GDF6 in M14 melanoma cells expressing an 
shRNA targeting EGFP or the GDF6-targeted shRNA GDF6.1. (G) Left, colony 
formation assay with A375 cells expressing an shRNA targeting EGFP or two 
independent GDF6-targeted shRNAs. Error bars indicate s.e.m.; n=3. Right, 
colony formation assay with M14 cells expressing an shRNA targeting EGFP or 
the GDF6-targeted shRNA GDF6.1. Error bars indicate s.e.m.; n=3. (H) Left, 
tumor formation in mice injected with A375 cells (1x107 cells injected per mouse) 
expressing an shRNA targeting EGFP or two independent GDF6-targeted 
shRNAs. Right, tumor formation in mice injected with M14 cells (1x107 cells 
injected per mouse) expressing an shRNA targeting EGFP or the GDF6-targeted 
shRNA GDF6.1. Error bars indicate s.e.m.; n=3. Two-tailed Student’s t-test, **P< 
0.01, ***P< 0.001, ns, not significant. For figure panels 1E and 1H, two-tailed 
Student’s t-test was performed by comparing tumor volumes of two groups at a 
given time point.   
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p53, as expression of gdf6b in Tg(mitfa:BRAFV600E) transgene (n=33) or p53(lf) 
(n=24) backgrounds alone did not produce tumors.  
We next assayed the consequences of GDF6 loss in vivo using a 
zebrafish melanoma model. Since gdf6a loss-of-function animals were previously 
established (Gosse and Baier, 2009), we used these mutants to test the role of 
GDF6 loss in melanoma onset. We bred a gdf6a loss-of-function mutation into 
tumor-prone Tg(mitfa:BRAFV600E); p53(lf) zebrafish and found that the resulting 
Tg(mitfa:BRAFV600E); p53(lf); gdf6a(lf) mutant animals had substantially 
delayed melanoma onset as compared to control siblings (Figure 2.6B). Together 
these results indicate that GDF6 ortholog activity is important for melanoma 
initiation: overexpression of gdf6b caused accelerated tumor onset, whereas loss 
of gdf6a caused a delay in disease onset.  
We also found that gdf6a-mutant zebrafish had a profoundly altered 
pigmentation pattern. An increase in melanocytes in the flank of gdf6a-mutant 
homozygotes was observed, whereas wild-type siblings had normal pigmentation 
(Figure 2.5C). In combination with our findings above that increased expression 
of GDF6 orthologs caused a reduction in the number of embryonic melanocytes, 
we speculate that these genes have a role in inhibiting melanocyte development.  
 
GDF6 modulation affects tumorigenicity of human melanoma cells 
 We next wanted to test if GDF6 modulation altered the growth of human 
melanoma cells. We first identified cell lines with GDF6 amplification (A375, SK-
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MEL-28 and SK-MEL-5) and others without amplification (M14, C32)(Forbes et 
al., 2017). Those with amplification had higher levels of GDF6 protein as 
compared to the non-amplified lines (Figure 2.6C). We overexpressed GDF6 in 
A375, SK-MEL-28 and M14 melanoma cells (Figure 2.6D and Figure 2.7A), 
followed by transplantation into immunocompromised mice. In each case 
elevation of GDF6 expression elevated tumor-forming potential as compared to 
empty vector controls (Figure 2.6E and Figure S2.7, B and C). GDF6 
overexpression also caused an increase in colony-forming potential of A375 
cells, indicating that it can also enhance tumorigenic capacity in vitro (Figure 
2.7D). These data indicate that increased GDF6, regardless of its endogenous 
levels, can promote tumorigenicity of melanoma cells. 
To determine the effects of GDF6 loss, we knocked down endogenous 
GDF6 in melanoma cells with amplifications and normal copy number of the 
GDF6 locus. Knockdown in amplified A375, SK-MEL-28 and SK-MEL-5 cells led 
to a growth disadvantage in vitro, as measured by anchorage-dependent colony 
formation (Figure 2.6, F and G, and Figure 2.7, E and F). In xenografts of A375 
and SK-MEL-28 cells with GDF6 knockdown we observed a substantial reduction 
in tumorigenic potential as compared to control cells with EGFP knockdown 
(Figure 2.6H and Figure 2.7G). However, knockdown of GDF6 in non-amplified 
M14 and C32 cells caused little change in anchorage-dependent colony 
formation (Figure 2.6, F and G, and Figure 2.7, E and F). In addition, in 
xenografts there was no change in the tumor-forming potential of M14 cells with  
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Figure 2.7: GDF6 modulation alters the tumorigenicity of human melanoma 
cells 
(A) Immunoblots of GDF6 and GAPDH from SK-MEL-28 melanoma cells 
overexpressing GDF6. (B) Tumor formation in mice injected with SK-MEL-28 
cells (1x106 cells injected per mouse) overexpressing GDF6 or empty vector 
control. Error bars indicate s.e.m.; n=3. (C) GDF6 staining of mouse xenografts 
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with A375 melanoma cells overexpressing GDF6 as compared to empty vector 
control. Scale bars, 50 µm. Single cells are shown on the right. (D) Soft agar 
assay with A375 melanoma cells overexpressing GDF6. Error bars indicate 
s.e.m.; n=3. (E) Immunoblots of GDF6 and GAPDH in melanoma cells (labeled at 
top) expressing shEGFP or shGDF6.1. (G) Colony formation assay with 
melanoma cells (indicated above) expressing shEGFP or shGDF6.1. Error bars 
indicate s.e.m.; n=3. (H) Tumor formation in mice injected with SK-MEL-28 cells 
(1x107 cells injected per mouse) expressing an shRNA targeting EGFP or the 
GDF6-targeted shRNA, GDF6.1. Error bars indicate s.e.m.; n=3. (I) Immunoblots 
of phospho-SMAD1/5/8, total SMAD1/5/8 and GAPDH in melanoma cell lines 
(indicated above) overexpressing GDF6 or empty vector control. Two-tailed 
Student’s t-test, *P< 0.05, **P< 0.01, ***P< 0.001. For figure panels S5B and 
S5G, two-tailed Student’s t-test was performed by comparing tumor volumes of 
two groups at a given time point. 
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GDF6 knockdown as compared to control M14 cells with EGFP 
knockdown (Figure 2.6H). Therefore, whereas all cells examined displayed 
increased tumorigenic potential upon GDF6 overexpression, only cells with 
amplification and higher levels of GDF6 protein were sensitive to GDF6 
knockdown. These results suggest that GDF6 does not serve a housekeeping 
function, but that cells with GDF6 amplification and high expression have 
become dependent on it for their tumorigenic potential. 
 
BMP signaling is active in melanomas and is driven by GDF6 ligand 
 Encoding BMP ligands, GDF6 genes are predicted to act through 
SMAD1/5/8 transcription factors. For this reason we investigated whether SMAD-
dependent signaling was activated in melanomas. Using an antibody that 
specifically recognizes phosphorylated SMAD1/5/8 proteins to monitor BMP 
pathway activity, we found robust phospho-SMAD1/5/8 nuclear staining in 
zebrafish melanomas (Figure 2.8A). Furthermore, transcriptome analyses 
indicated upregulation in zebrafish melanomas of genes that support BMP 
signaling, including the BMPR1A and BMPR2 receptor subunits, through which 
GDF6 is known to act (Wang et al., 2013b)(Figure 2.8B). gdf6a and gdf6b were 
the only BMP ligands upregulated in zebrafish melanomas leading us to 
hypothesize that BMP signaling in melanomas is largely dependent on GDF6 
(Figure 2.8C). To address this hypothesis we modulated GDF6 activity in human 
melanoma cells. GDF6 knockdown caused a profound reduction in phospho- 
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Figure 2.8: GDF6-dependent BMP activity in melanomas 
(A) Transverse sections of a Tg(mitfa:BRAFV600E);p53(lf) zebrafish bearing an 
invasive melanoma in the dorsal musculature. Top, hematoxylin and eosin 
staining. Bottom, phospho-SMAD1/5/8 staining. Left, scale bar, 500 µm. Right, 
scale bar, 50 µm. For phospho-SMAD1/5/8 staining, normal muscle (top) and a 
tumor region (bottom) are shown. Note that normal scale tissue (running 
vertically through middle of image) in the tumor region is phospho-SMAD1/5/8 
negative. T, tumor. N, normal. (B) Heat map of gene expression of BMP pathway 
genes (Reactome gene set R-HSA-201451.3) in zebrafish melanomas as 
  
52 
compared to melanocytes. Human orthologs of zebrafish genes are displayed. 
(C) Log2-transformed fold change of gene expression in zebrafish melanomas as 
compared to melanocytes (y-axis). Expression of BMP ligands in microarray 
analysis (left) and RNAseq analysis (right). Only BMP ligands with a significant 
dysregulation (adjusted p-value<0.05) are shown. (D) Immunoblots of phospho-
SMAD1/5/8 and total SMAD1/5/8 in A375 melanoma cells expressing an shRNA 
targeting EGFP or two independent GDF6-targeted shRNAs. (E) Aggregation 
plot of phospho-SMAD1/5/8 ChIPseq enrichment at annotated transcriptional 
start sites (TSSs) in A375 melanoma cells expressing an shRNA targeting EGFP 
or the GDF6-targeted shRNA, GDF6.1. ***P < 2.2e-16 by two-sample 
Kolmogorov-Smirnov test after summing TSS-proximal reads (-2kb to 2kb) for 
each gene (n=49,344 TSSs). (F) Tumor formation in mice injected with A375 
cells (1x106 cells injected per mouse) treated with vehicle control or 25 mg/kg 
DMH1 every other day. Error bars indicate s.e.m.; n=8. (G) Tumor formation in 
mice injected with A375-empty or A375-SMAD1DVD cells expressing two 
independent GDF6-targeted shRNAs. Each mouse was injected with 1x107 cells. 
Error bars indicate s.e.m.; n=3. Two-tailed Student’s t-test, **P< 0.01, ***P< 
0.001.  
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SMAD1/5/8 levels (Figure 2.8D), whereas GDF6 overexpression led to an 
increase in phospho-SMAD1/5/8 (Figure 2.7H). Phospho-SMAD1/5/8 proteins 
translocate to the nucleus where they, in complexes with SMAD4 and/or other 
regulatory proteins, bind DNA and modulate transcription of target genes. To 
determine if GDF6 regulates SMAD1/5/8 DNA-binding activity, we performed 
chromatin immunoprecipitation and massively parallel sequencing (ChIPseq) of 
phospho-SMAD1/5/8 in control and GDF6 knockdown A375 melanoma cells. 
Binding of phospho-SMAD1/5/8 to promoter regions of target genes was 
markedly reduced upon GDF6 knockdown (Figure 2.8E). Likewise, in a broader 
consideration of all phospho-SMAD1/5/8 bound regions, knockdown of GDF6 
caused a general reduction in binding (Figure 2.9A). Reduction in binding was in 
many cases accompanied by transcriptional changes; for example, reduced 
binding and transcriptional downregulation co-occurred at the well-established 
phospho-SMAD1/5/8 target genes ID1 and ID3 (Figure 2.9, B and C). Based on 
these results, BMP signaling is active in melanomas, and much of this activity is 
driven by GDF6. 
 
GDF6 acts via the BMP-SMAD pathway to promote tumor progression 
To test if the role of GDF6 in promoting melanoma progression is 
mediated by the SMAD1/5/8 axis of BMP signaling, we modulated pathway 
activity in A375 cells. Knockdown of SMAD1 led to defects in cell growth and 
tumorigenic potential (Figure 2.10, A-C), like what was observed in GDF6  
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Figure 2.9: GDF6 knockdown impairs BMP pathway activity 
(A) Comparison of ChIPseq maps of phospho-SMAD1/5/8 binding in control and 
GDF6-depleted cells. The heat map extends from -2kb to +2kb from the center of 
each bound region, with each row representing a unique bound region and 
enrichment denoted in red. The heat map is sorted based on phsopho-
SMAD1/5/8 binding in control cells. (B) phospho-SMAD1/5/8 binding to the ID1 
locus (top) and ID3 locus (bottom) in A375 melanoma cells expressing shEGFP 
or shGDF6.1. (C) qRT-PCR showing expression of ID1 (top) and ID3 (bottom) in 
A375-empty or A375-SMAD1DVD cells expressing an shRNA targeting EGFP or 
two independent GDF6-targeted shRNAs. Left two brackets, ID gene expression 
is downregulated upon GDF6 knockdown. Right two brackets, downregulation of 
ID gene expression is reversed in SMAD1DVD-expressing cells upon GDF6 
knockdown. Error bars indicate s.e.m.; n=3. Two-tailed Student’s t-test, ***P< 
0.001. 
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Figure 2.10: GDF6 acts through SMAD1 to promote melanoma progression 
(A) Immunoblots showing expression of SMAD1 and GAPDH in A375 melanoma 
cells expressing shEGFP, shSMAD1.1 or shSMAD1.2. (B) Colony formation 
assay with A375 cells expressing shEGFP, shSMAD1.1 or shSMAD1.2. Error 
bars indicate s.e.m.; n=3. (C) Tumor formation in mice injected with A375 cells 
expressing shEGFP or shSMAD1.2. Error bars indicate s.e.m.; n=3. (D) 
Immunoblots showing expression of phospho-SMAD1/5/8 and total SMAD1/5/8 
in A375 melanoma cells after treatment with 0.1% DMSO (vehicle) or 10µM 
DMH1 in 0.1% DMSO. (E) Colony formation assay with A375 cells treated with 
0.1% DMSO (vehicle) or 10µM DMH1 in 0.1% DMSO. Error bars indicate s.e.m.; 
n=3. (F) Immunoblots showing expression of Flag-tagged SMAD1DVD and 
GAPDH in control and A375-SMAD1DVD cells. (G) Colony formation assay with 
A375-EMPTY or A375-SMAD1DVD cells expressing shEGFP, shGDF6.1 or 
shGDF6.2. Error bars indicate s.e.m.; n=3. (H) Tumor formation in mice injected 
with A375-empty or A375-SMAD1DVD cells expressing an EGFP-targeted 
shRNA. Each mouse was injected with 1x107 cells. Error bars indicate s.e.m.; 
n=3. (I) Colony formation assay with A375-empty or A375-SMAD1DVD cells 
treated with 0.1% DMSO (vehicle) or 10µM DMH1 in 0.1% DMSO. Error bars 
indicate s.e.m.; n=3. Two-tailed Student’s t-test, **P< 0.01, ***P< 0.001, ns, not 
significant. 
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knockdown cells. We also used a small molecule inhibitor of BMP signaling, 
DMH1, to block pathway activity. DMH1 can suppress growth of BMP-dependent 
ovarian and lung cancer cells (Hao et al., 2014; Hover et al., 2015), but its 
efficacy in melanoma has not been reported. DMH1 inhibits kinase activity of 
ALK2 and BMPR1A (ALK3) receptors but not of BMPR1B (ALK6), thereby 
abrogating phosphorylation and activation of the SMAD1/5/8 transcriptional 
cascade (Hao et al., 2010). GDF6 has been shown to act through BMPR1A 
(ALK3) (Wang et al., 2013b), and we found that treatment with DMH1 reduced 
phospho-SMAD1/5/8 levels and decreased cell growth and tumorigenicity (Figure 
2.8F and Figure 2.10, D and E). To test the relationship of GDF6 to SMAD1 in 
genetic epistasis analyses, we expressed a phosphomimetic variant of SMAD1, 
SMAD1DVD, in A375 cells (Figure 2.10F)(Tsukamoto et al., 2014). Whereas 
GDF6 knockdown abrogated cell growth and tumorigenic potential of A375 
control cells, A375-SMAD1DVD cells subjected to GDF6 knockdown were 
rescued, exhibiting robust growth in colony formation and xenotranplantation 
assays (Figure 2.8G and Figure 2.10, G and H) Growth defects caused by 
treatment with DMH1 were also reversed by SMAD1DVD (Figure 2.10I). 
Together these data indicate that GDF6 signals via SMAD-dependent BMP 
signaling to promote tumorigenesis, and inhibition of this signaling achieves a 
reduction in tumor growth.  
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GDF6-dependent BMP signaling maintains a trunk neural crest gene 
signature 
 Since GDF6 acts through SMAD transcription factors, we were interested 
in identifying gene expression changes that could illuminate how this signaling 
axis regulates tumorigenesis. To do this, we modulated GDF6 and SMAD1 and 
sought genes commonly regulated by both. Based on our genetic epistasis 
results, we predicted that expression of important genes would change upon 
GDF6 knockdown but such changes would be reversed when GDF6 knockdown 
was rescued by SMAD1DVD. Using RNAseq, we defined the set of genes that 
was differentially regulated upon GDF6 knockdown and showed reciprocal 
differential regulation in SMAD1DVD-expressing cells that were subjected to 
GDF6 knockdown (Figure 2.11A). Pathway analysis showed that this gene set 
most significantly overlapped with genes involved in ossification and neural crest 
development (Figure 2.11B). GDF6-SMAD regulation of neural crest genes is 
intriguing since melanocytes initially develop from this embryonic tissue. Several 
genes upregulated by GDF6 and SMAD1DVD – SOX10, TFAP2B, FOXD3, 
SNAI2 - are neural crest ‘specifiers’, genes that are expressed broadly in the 
neural crest and help to maintain neural crest identity (Figure 2.11C)(Sauka-
Spengler and Bronner-Fraser, 2008). SOX9 is initially broadly expressed in the 
neural crest, but as development proceeds its expression becomes excluded 
from trunk neural crest and limited to cranial neural crest, from which 
mesenchymal tissues such as craniofacial cartilage are derived. Conversely,  
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Figure 2.11: GDF6 and SMAD1 regulate a neural crest gene signature in 
melanomas 
(A) Genes differentially regulated in A375 melanoma cells upon GDF6 
knockdown (purple circle) and genes reciprocally regulated in SMAD1DVD-
expressing A375 cells upon GDF6 knockdown (green circle). (B) Pathway 
analysis with the 605 reciprocally regulated genes (minimum overlap ≥ 10 genes; 
adjusted P-value < 0.01). (C) Heat map of neural crest genes identified in 
pathway analysis.  
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SOX10 expression becomes restricted to trunk neural crest from which non-
mesenchymal cells, including melanocytes, develop. Since SOX10 is 
upregulated and SOX9 is downregulated by GDF6-SMAD signaling, the pattern 
of gene regulation most closely resembles trunk neural crest tissue. Adopting a 
neural crest-like identity can contribute to the aggressive nature of melanoma 
cells (Hendrix et al., 2007; Hoek and Goding, 2010). For these reasons we 
hypothesized that GDF6-driven BMP signaling (GDF6-SMAD), by promoting a 
trunk neural crest gene signature, enables melanoma cells to adopt and maintain 
an undifferentiated, pro-tumorigenic state.  
 
GDF6 inhibits melanoma cell differentiation by repressing MITF 
 To determine how GDF6-driven BMP signaling could regulate the 
differentiation of melanoma cells, we considered target genes that were bound by 
phospho-SMAD1/5/8 and transcriptionally regulated in a GDF6-dependent 
manner. Among these genes was MITF, the master regulator of melanocyte 
differentiation. In control A375 cells, phospho-SMAD1/5/8 binding was observed 
in the MITF locus in a region that is intronic for longer MITF isoforms and 
upstream of the smaller MITF-M isoform, the predominant species of MITF in 
melanocytes and melanomas (Figure 2.12A)(Fuse et al., 1996). Binding to this 
region was abrogated in GDF6 knockdown cells. This loss of binding in GDF6 
knockdown melanoma cells was coupled with a transcriptional increase in MITF 
(Figure 2.12B). MITF itself is a transcriptional factor that orchestrates  
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Figure 2.12: GDF6-induced BMP signaling blocks melanoma cell 
differentiation 
(A) phospho-SMAD1/5/8 binding to the MITF locus in A375 melanoma cells 
expressing an shRNA targeting EGFP or the GDF6-targeted shRNA, GDF6.1. 
Traces of two independent biological replicates are shown. (B) qRT-PCR 
showing expression of MITF in A375-empty or A375-SMAD1DVD cells 
expressing an shRNA targeting EGFP or the GDF6-targeted shRNA, GDF6.1. 
(C) qRT-PCR of TRP1 under the same conditions. Left brackets, MITF or TRP1 
expression is upregulated upon GDF6 knockdown. Right brackets, MITF or TRP1 
expression is less upregulated in SMAD1DVD-expressing cells upon GDF6 
knockdown. Error bars indicate s.e.m.; n=3. (D) qRT-PCR showing expression of 
mitfa (left) and trp1b (right) in control and gdf6a(lf) zebrafish melanomas. Error 
bars indicate s.e.m.; n=3. (E) Hematoxylin and eosin staining of transverse 
sections from Tg(mitfa:BRAFV600E);p53(lf) (top) and 
Tg(mitfa:BRAFV600E);p53(lf);gdf6a(lf) (bottom) zebrafish melanomas invading 
the dorsal musculature. Left scale bars, 100 µm. Right scale bars, 25 µm. Two-
tailed Student’s t-test, *P<0.05, **P< 0.01, ***P< 0.001. 
  
  
62 
differentiation, in part, by activating expression of melanin biosynthesis genes. 
The increase in MITF upon GDF6 knockdown was accompanied by an increase 
in the melanin biosynthesis gene TRP1 (Figure 2.12C), indicating that 
melanocyte differentiation was invoked upon GDF6 loss. Upregulation of MITF 
and TRP1 was less pronounced when GDF6 knockdown was performed in 
SMAD1DVD-expressing cells (Figure 2.12, B and C). Depending on cofactors 
involved, phospho-SMAD1/5/8 can promote transcription, as with ID1 and ID3, or 
repress transcription, as we propose for MITF (Massague et al., 2005). To 
determine if GDF6 regulates differentiation of melanomas in vivo, we examined 
tumors that arose in Tg(mitfa:BRAFV600E); p53(lf); gdf6a(lf) zebrafish. 
Melanomas from these animals had increased transcript levels of mitfa and 
trp1b, orthologs of the human MITF and TRP1 genes (Figure 2.12D). 
Furthermore, gdf6a mutant tumors exhibited a profound increase in melanization 
as compared to control tumors (Figure 2.12E). Based on these results, GDF6 
maintains melanomas in an undifferentiated state, and we speculate that 
preventing differentiation helps melanoma cells retain a neural crest identity.  
 
GDF6 represses SOX9 to promote melanoma cell survival 
Knockdown of GDF6 and SMAD1 caused defects in melanoma cell 
growth. We sought to understand this defect and whether the trunk neural crest 
signature was involved. A variety of analyses suggested that the growth defect 
was linked to regulation of apoptosis. Specifically, gene set enrichment analysis 
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(GSEA) revealed that GDF6 expression negatively correlated with expression of 
apoptotic pathway genes both in cells with GDF6 modulation as well as in patient 
samples (Figure 2.13A and Figure 2.14, A and B). In direct assessments, GDF6 
loss increased apoptotic cell death in A375 cells as well as in vivo in zebrafish 
melanomas and mouse xenografts (Figure 2.13, B and C, and Figure 2.14, C-E). 
By contrast, GDF6 overexpression xenografts showed reduced apoptotic cell 
death as compared to basal levels of cell death in control xenografts (Figure 
2.14, F and G). GDF6 overexpression xenografts had a slightly increased Ki67 
proliferative index, suggesting that the reduction in cell death was not caused by 
a failure to generate new cells with the potential to die (Figure 2.14H). Finally, the 
cell death caused by GDF6 knockdown was rescued by SMAD1DVD expression, 
indicating that GDF6 acts via BMP signaling to promote melanoma cell survival 
(Figure 2.13D and Figure 2.15). The involvement of GDF6 in cell death is 
consistent with findings in which loss of GDF6 orthologs in fish and Xenopus 
caused a substantial increase in apoptosis during eye and neural development 
(Asai-Coakwell et al., 2013; Hanel and Hensey, 2006; Pant et al., 2013). We 
speculate that GDF6 knockdown causes terminal differentiation of melanoma 
cells, leading to cell cycle exit followed by cell death.  
To determine how GDF6 and BMP signaling regulate melanoma cell survival, we 
focused on the reciprocally regulated genes defined previously. In particular, 
SNAI2 and SOX9 were assessed because of their importance in specifying 
neural crest and regulating cell survival  
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Figure 2.13: GDF6 and BMP signaling repress SOX9 to promote melanoma 
cell survival  
(A) GSEA shows that expression of an apoptotic gene set (MSigDB- M10169) is 
negatively enriched in GDF6-overexpressing A375 cells. (B) Caspase-3/7 activity 
measured as relative luciferase units (RLU) in A375 cells upon GDF6 
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knockdown. Error bars indicate s.e.m.; n=3. (C) Fluorescent TUNEL staining of 
Tg(mitfa:BRAFV600E);p53(lf) (left) or Tg(mitfa:BRAFV600E);p53(lf);gdf6a(lf) 
(right) zebrafish melanoma sections. TUNEL (green), DAPI (blue), and a merged 
image of both channels is shown. Scale bar, 25 µm. Error bars indicate s.e.m.: 
n= 100 fields. (D) TUNEL staining of mouse xenografts of A375 cells expressing 
SMAD1DVD upon GDF6 knockdown. Scale bar, 25µm. Error bars indicate 
s.e.m.; n=100 fields. (E) Immunoblots showing expression of SOX9 and GAPDH 
in A375-empty or A375-SMAD1DVD cells expressing an shRNA targeting EGFP 
or the GDF6-targeted shRNA, GDF6.1. (F) Caspase-3/7 activity measured as 
relative luciferase units (RLU) in A375-non-silencing (NS) or A375-shSOX9 cells 
expressing an shRNA targeting EGFP or the GDF6-targeted shRNA, GDF6.1. 
Error bars indicate s.e.m.; n=3. (G) Tumor formation in mice injected with A375-
non-silencing or A375-shSOX9 cells expressing two independent GDF6-targeted 
shRNAs. Each mouse was injected with 1x106 cells. Error bars indicate s.e.m.; 
n=3. Two-tailed Student’s t-test, **P< 0.01, ***P< 0.001. 
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Figure 2.14: GDF6 knockdown causes melanoma cell death 
(A) GSEA shows that expression of an apoptotic gene set (MSigDB- M10169) is 
positively enriched in GDF6-knockdown A375 cells (B) GSEA shows that 
expression of an apoptotic gene set (MSigDB- M10169) is negatively enriched in 
patient-derived melanomas (TCGA) expressing high levels of GDF6. (C) Flow 
cytometry analysis of annexinV-positivity of A375 cells upon GDF6 knockdown. 
Error bars indicate s.e.m.; n=3. (D) TUNEL staining of mouse xenografts of A375 
cells upon GDF6 knockdown. Scale bar, 25µm. Error bars indicate s.e.m.; n=100 
fields. (E) Cleaved Caspase-3-staining of mouse xenografts of A375 cells upon 
GDF6 knockdown Scale bar, 25µm. Error bars indicate s.e.m.; n=100 fields. (F) 
TUNEL staining of mouse xenografts of A375 cells upon GDF6 overexpression. 
Scale bar, 25µm. Error bars indicate s.e.m.; n=100 fields. (G) Cleaved Caspase-
3-staining of mouse xenografts of A375 cells overexpressing GDF6 or empty 
vector control. Scale bar, 25µm. Error bars indicate s.e.m.; n=100 fields. (H) Ki-
67 staining of mouse xenografts of A375 cells overexpressing GDF6 or empty 
vector control. Scale bar, 25µm. Right, quantification of Ki67-positive cells (Ki-67 
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index); Error bars indicate s.e.m.; n=100 fields. Two-tailed Student’s t-test, *P< 
0.05, **P< 0.01, ***P< 0.001. 
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Figure 2.15: GDF6 knockdown-induced cell death is rescued by SMAD1DVD 
(A) Caspase-3/7 activity measured as relative luciferase units (RLU) in A375-
empty or A375-SMAD1DVD cells expressing an shRNA targeting EGFP or the 
GDF6-targeted shRNA, GDF6.1. Error bars indicate s.e.m.; n=3. (B) Flow 
cytometry analysis of annexinV-positivity of A375-empty or A375-SMAD1DVD 
cells expressing an shRNA targeting EGFP or the GDF6-targeted shRNA, 
GDF6.1. Error bars indicate s.e.m.; n=3. (C) Cleaved Caspase-3 staining of 
mouse xenografts of A375-empty or A375-SMAD1DVD cells expressing an 
shRNA targeting EGFP or the GDF6-targeted shRNA GDF6.1. Scale bar, 25µm. 
Error bars indicate s.e.m.; n=100 fields. Two-tailed Student’s t-test, **P< 0.01, 
***P< 0.001. 
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(Cheung and Briscoe, 2003; Greenhill et al., 2011; Kajita et al., 2004; Shakhova 
et al., 2015). Whereas modulation of SNAI2 had no effect on GDF6-driven 
survival (Figure 2.16), SOX9 was intimately involved. In studying SOX9, we first 
confirmed that changes in GDF6 and BMP signaling affected SOX9 expression. 
A375 cells with GDF6 knockdown had increased SOX9 RNA and protein levels, 
and this increase was much less pronounced in SMAD1DVD cells that were 
subjected to GDF6 knockdown (Figure 2.13E and Figure 2.17A). Additionally, 
gdf6a mutant zebrafish melanomas showed elevated sox9b levels (Figure 
2.17B). To determine if GDF6 mediates cell survival by regulating SOX9 we 
measured whether knockdown of SOX9 (Figure 2.17, C and D) could suppress 
the growth defects and cell death resulting from GDF6 knockdown. In colony 
formation assays, cells with combined knockdown of SOX9 and GDF6 grew 
much better than did GDF6 single knockdown cells (Figure 2.17E). Similarly, cell 
death, as measured by caspase-3 cleavage and annexinV positivity, was greatly 
reduced in GDF6/SOX9 double knockdown cells (Figure 2.13F and Figure 
2.17F). Lastly, the ability of SOX9 knockdown to rescue the tumor-forming 
capacity of GDF6 knockdown cells was measured. When performed together 
with GDF6 knockdown, SOX9 knockdown enabled cells to engraft and rapidly 
grow (Figure 2.13G and Figure 2.17G).  These data indicate that a major function 
of GDF6 is to repress SOX9 expression, thereby inhibiting cell death and 
promoting tumor growth. 
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Figure 2.16: SNAI2 overexpression does not rescue growth defects and cell 
death caused by GDF6 knockdown 
(A) qRT-PCR showing expression of SNAI2 in A375-empty or A375-SNAI2 cells 
expressing shEGFP or shGDF6.1. Error bars indicate s.e.m.; n=3. Left bracket, 
SNAI2 expression is downregulated upon GDF6 knockdown. Right bracket, 
SNAI2 overexpression in GDF6 knockdown cells. (B) Colony formation assay of 
A375-empty (top) or A375-SNAI2 (bottom) cells expressing an shRNA targeting 
EGFP or two independent GDF6-targeted shRNAs. Error bars indicate s.e.m.; 
n=3. (C) Caspase-3/7 activity measured as relative luciferase units (RLU) in 
A375-empty or A375-SNAI2 cells expressing shEGFP or shGDF6.1. Error bars 
indicate s.e.m.; n=3. (D) Flow cytometry analysis of annexinV-positivity of A375-
empty or A375-SNAI2 cells expressing shEGFP or shGDF6.1. Error bars indicate 
s.e.m.; n=3. Two-tailed Student’s t-test, ***P< 0.001. ns, not significant.  
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Figure 2.17: SOX9 knockdown rescues the growth defects and cell death 
caused by GDF6 knockdown 
(A) qRT-PCR of SOX9 in A375-empty or A375-SMAD1DVD cells with GDF6 
knockdown. Error bars indicate s.e.m.; n=3. Left bracket, SOX9 expression is 
upregulated upon GDF6 knockdown. Right bracket, SOX9 expression is less 
upregulated in SMAD1DVD-expressing cells upon GDF6 knockdown. (B) qRT-
PCR showing expression of sox9b in control and gdf6a(lf) zebrafish melanomas. 
Error bars indicate s.e.m.; n=3. (C) qRT-PCR showing expression of SOX9 in 
A375-non-silencing or A375-shSOX9 cells with GDF6 knockdown. Error bars 
indicate s.e.m.; n=3. Left bracket, SOX9 expression is upregulated upon GDF6 
knockdown. Right bracket, knockdown of SOX9 expression in GDF6 knockdown 
cells. (D) Immunoblots showing expression of SOX9 and GAPDH in A375-non-
silencing or A375-shSOX9 cells expressing shEGFP or shGDF6.1. (E) Colony 
formation assay with A375-non-silencing (top) or A375-shSOX9 (bottom) cells 
expressing an shRNA targeting EGFP or two independent GDF6-targeted 
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shRNAs. Error bars indicate s.e.m.; n=3. (F) Flow cytometry analysis of 
annexinV-positivity of A375-non-silencing or A375-shSOX9 cells expressing 
shEGFP or shGDF6.1. (G) Tumor formation in mice injected with A375-non-
silencing or A375-shSOX9 cells expressing an shRNA targeting EGFP. Error 
bars indicate s.e.m.; n=3. Two-tailed Student’s t-test, **P< 0.01, ***P< 0.001.  
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Clinical significance of GDF6 expression and signaling 
 We next assessed expression of GDF6 in human melanomas and 
examined potential clinical implications. Immunohistochemistry on an initial 
cohort of patient samples detected high levels of GDF6 protein in melanomas; 
however, normal melanocytes of adjacent skin (Figure 2.18A) or tumor-infiltrating 
cells (Figure 2.19) rarely expressed GDF6. In the same cohort, we found high 
BMP pathway activity, as measured by nuclear phospho-SMAD1/5/8 staining, in 
tumor cells but not in normal tissue (Figure 2.18A and Figure 2.19). To determine 
whether expression of GDF6 correlated with melanoma patient clinical 
characteristics, we performed immunohistochemistry on a microarray with 104 
melanoma tissue cores (78 primary and 26 metastatic melanomas). Consistent 
with the initial cohort, robust GDF6 expression was observed in a majority of 
melanomas (80% of total; n=104 cases). Importantly, in analyzing clinical aspects 
of the melanoma tissue microarray, we found that patients whose tumors at 
diagnosis expressed high amounts of GDF6 had a lower survival probability than 
did patients whose tumors expressed no or low GDF6 (Figure 2.18B and Table 
2.1). This association was mainly driven by patients with primary melanomas 
(Figure 2.20A). Additionally, GDF6 expression in primary melanomas significantly 
correlated with lymph node metastasis (Figure 2.18C). In these primary 
melanomas, expression of GDF6 tended to be higher than in metastatic lesions 
(Figure 2.20B). Together, these data indicate that GDF6 is a negative prognostic 
marker for early stage melanomas.  
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Figure 2.18: Clinical impact of GDF6 expression and BMP pathway 
inhibition  
(A) Staining of adjacent normal skin and melanoma tissue from the same section. 
Left, hematoxylin and eosin. Center, GDF6 immunostaining. Right, phospho-
SMAD1/5/8 immunostaining. Melanocytes in normal skin sections are indicated 
(arrowheads). Scale bar, 25µm. Images of individual cells are shown immediately 
to the right. Below GDF6 and phospho-SMAD1/5/8 images the percentages of 
patient samples with no or low, and high expression of these proteins in normal 
melanocytes and melanomas is indicated. (B) Left, percentages of patient 
samples with no or low, and high GDF6 expression in the melanoma tissue 
microarray. Right, Kaplan-Meier analysis for the melanoma tissue microarray 
samples showing overall survival of patients with no or low GDF6 expression 
(blue line) versus high GDF6 expression (red line). Statistical analysis was 
performed with a Mantel-Cox log rank test. (C) GDF6 staining score in patients 
with primary melanomas with (n=61) or without (n=19) lymph node metastasis. 
Two-tailed Welch’s t-test **P<0.01. (D) Mice bearing A375 xenografts were 
treated with vehicle, DMH1, dabrafenib+trametinib or a combination of all three 
drugs. Normalized tumor volumes following the beginning of drug treatments are 
shown. Error bars indicate s.e.m.; n≥8 animals. (E) Model for GDF6 activation 
and function in melanomas. **P< 0.01 two-tailed Student’s t-test (C) or by one-
way ANOVA with Bonferroni test (D). ##P< 0.001 by one-way ANOVA (D). 
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Figure 2.19: GDF6 and phospho-SMAD1/5/8 expression in a patient 
melanoma section  
Section of a metastatic human melanoma (M) with tumor infiltrating lymphoycytes 
(TIL). Top, hematoxylin and eosin staining. Middle, GDF6 staining. Bottom, 
phospho-SMAD1/5/8 staining. Left, scale bar, 50 µm. Center and right, 
melanoma region and TIL region, respectively. Scale bar, 25 µm.  
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Group Hazard Ratio P-value 
GDF6 expression 2.07 0.04 
Age 1.41 0.16 
Sex (Female vs Male) 0.27 0.79 
Tstage (3vs2) -0.44 0.66 
Tstage (4vs2) 1.46 0.14 
Metastatic vs Primary 0.11 0.91 
 
 
Table 2.1 Multivariate analysis using the tissue microarray with melanoma patient 
samples  
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Figure 2.20: Correlation of GDF6 expression with melanoma clinical 
features 
(A) Kaplan-Meier analysis showing overall survival of patients (melanoma tissue 
microarray) with primary melanomas (left) and metastatic melanomas (right) with 
no or low GDF6 expression (blue line) versus high GDF6 expression (red line). 
Statistical analysis was performed with a Mantel-Cox log rank test. (B) GDF6 
expression score in primary and metastatic melanomas from the melanoma 
tissue microarray. Two-tailed Welch’s t-test, **P< 0.01.  
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Next, we wanted to test whether targeting GDF6-driven BMP signaling could be 
combined with existing therapies. We treated established A375 melanoma 
xenografts with DMH1 or dabrafenib+trametinib or a combination of all three 
drugs. While treatment with dabrafenib+trametinib caused substantial regression, 
the combination of DMH1 with dabrafenib+trametinib showed even further 
regression (Figure 2.18D). Treatment with DMH1 alone had little effect, although 
we presume that it does not fully inhibit GDF6-driven BMP signaling in vivo, as 
indicated by our previous experiments. These results indicate that targeting 
GDF6-driven BMP signaling in combination with current therapeutic strategies 
may have profound clinical benefits. 
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Discussion 
 
In this study, genomic and functional analyses identified GDF6 as a novel 
melanoma oncogene. Based on these and additional mechanistic studies, we 
propose the following model for the role of GDF6 in melanoma tumorigenesis 
(Figure 7E). First, during the course of melanomagenesis, the GDF6 locus is 
transcriptionally activated, in some cases stemming from copy number 
amplification. Production of GDF6 protein leads to either autocrine or paracrine 
activation of BMP pathway signaling in nascent melanoma cells. BMP signaling 
triggers SMAD1/5/8-dependent downregulation of MITF and SOX9, which inhibits 
melanoma cell differentiation and death, respectively. GDF6-dependent binding 
of SMAD1/5/8 to the MITF locus suggests downregulation in this case is direct.  
There are no SMAD1/5/8 bound regions in the SOX9 locus, so its downregulation 
is either indirect or mediated by long-range interactions with SMAD1/5/8 that is 
bound, in a GDF6-dependent fashion, to sites in neighboring loci. The outcome 
of this signaling is to promote a neural crest gene signature within melanoma 
cells, which enables tumor progression. 
 
GDF6 and BMP signaling in melanoma maintenance and initiation 
 BMP pathway activity has previously been implicated in melanoma 
progression. BMP4 and BMP7 expression has been shown to promote tumor cell 
invasion and migration in an autocrine fashion (Rothhammer et al., 2005), 
whereas BMP2 and BMP4 promote angiogenesis through paracrine signaling 
  
81 
(Rothhammer et al., 2007). Independent studies indicate that BMP7 can block 
melanoma cell growth and inhibit metastasis (Hsu et al., 2008; Na et al., 2009), 
suggesting BMP7’s effects on melanoma progression may be complex and 
potentially cell line-specific. More relevant to our studies, BMP signaling has 
been proposed to promote melanoma survival by inducing the anti-apoptotic 
factor DIDO1 (Braig and Bosserhoff, 2013). We tested whether DIDO1 is 
involved in the anti-apoptotic role of GDF6 in melanoma cells. Upon GDF6 
knockdown we did not observe changes in DIDO1 transcript levels. Furthermore, 
we found that while phospho-SMAD1/5/8 bound to a site within the DIDO1 gene, 
this site was not differentially bound upon GDF6 knockdown. Thus GDF6, via 
SOX9, likely interfaces with the cell death machinery through other factors. 
 Along with preventing cell death, our studies indicate that GDF6 and BMP 
signaling promote melanoma maintenance through additional mechanisms. 
GDF6 downregulates expression of MITF, which is likely accomplished by 
induction of phospho-SMAD1/5/8 and its direct binding to the MITF gene. MITF is 
a master regulator of the melanocyte lineage, and its regulation is critically 
important for the behaviors of cells within this lineage. MITF expression is 
governed by a variety of signals that ultimately produce an expression level that 
dictates cellular phenotype. In this way MITF is proposed to act as a rheostat 
(Carreira et al., 2006; Goding, 2011; Hoek and Goding, 2010). Specifically, high 
levels of MITF promote cell cycle arrest and terminal differentiation, whereas 
lower expression levels stimulate proliferation. Even lower levels endow cells 
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with stem cell-like and invasive properties. We speculate that by repressing 
MITF, GDF6 and BMP signaling keep MITF expression in a range that not only 
inhibits terminal differentiation but also protects against cell death and endows 
cells with properties important for tumor maintenance.  
 Our data also implicate GDF6 and BMP signaling in melanoma initiation. 
In zebrafish, cells in the melanocyte lineage that expressed gdf6b gave rise to 
melanomas more rapidly than did control cells. Furthermore, melanoma onset 
was delayed in gdf6a mutant zebrafish. Recently it was shown that cells of origin 
for zebrafish melanomas adopt neural crest characteristics that distinguish them 
from normal melanocytes (Kaufman et al., 2016). These neural crest 
characteristics are proposed to be instrumental in melanoma initiation. Given that 
GDF6 and its orthologs are melanoma oncogenes and they promote a neural 
crest gene signature, we speculate that GDF6 and BMP signaling are important 
at the earliest stages of melanoma formation.  
 
Reiteration of embryonic GDF6 activities in melanomas 
 GDF6 is expressed during embryogenesis, and its functions during 
development mirror those upon its reactivation in melanomas. In Xenopus and 
zebrafish embryos, GDF6 is expressed at the edges of the neural plate and in 
the eye fields of the anterior neural plate. Upon neural tube closure, expression is 
prominent in the dorsal neural tube and neural crest (Bruneau and Rosa, 1997; 
Hanel and Hensey, 2006; Reichert et al., 2013). Loss-of-function studies in both 
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species suggest that GDF6 promotes ectodermal cell survival (Delot et al., 1999; 
Hanel and Hensey, 2006). In Xenopus and zebrafish, knockdown of GDF6 and 
gdf6a, respectively, caused a reduction in eye size that resulted from 
inappropriate death of retinal neuron progenitor cells (Asai-Coakwell et al., 2009; 
Asai-Coakwell et al., 2013; Pant et al., 2013). GDF6 also acts during 
embryogenesis to regulate cell differentiation. In the mouse, Gdf6 inhibits 
differentiation of the mesenchymal progenitors that develop into the coronal 
suture, and precocious differentiation of these cells results in fusion (Clendenning 
and Mortlock, 2012; Settle et al., 2003). Thus, in certain tissues GDF6 can 
promote cell survival during development as well as regulate terminal 
differentiation.  
 We have found that GDF6 promotes a neural crest signature in melanoma 
cells. In particular, GDF6 maintains expression of the trunk neural crest factor 
SOX10 while repressing the cranial neural crest factor SOX9. Some data support 
a similar function for GDF6 in embryogenesis. As noted above, GDF6 orthologs 
in Xenopus and zebrafish are expressed in the neural crest and adjacent dorsal 
neural tube. In zebrafish, knockdown of gdf6a reduces expression of sox10 in 
neural crest cells (Reichert et al., 2013), consistent with a function in maintaining 
a trunk neural crest gene signature. As development proceeds, gdf6 paralog 
expression is progressively lost in a rostrocaudal direction, which occurs 
concomitantly with rostrocaudal differentiation of crest cells, including 
melanocytes. Perhaps the loss of gdf6 expression removes a barrier to 
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melanocyte differentiation. Support for such a barrier has been shown in avian 
embryos, where BMP4-driven pathway activity inhibits melanocyte fate 
specification during neural crest lineage segregation (Jin et al., 2001). We 
speculate that GDF6 may activate BMP signaling in the neural crest to repress 
MITF. With MITF repressed, neural crest cells can remain undifferentiated and 
responsive to proliferative signals as well as those that specify alternative cell 
fates. In melanomas BMP signaling likewise could promote a neural crest cell 
identity that is not terminally differentiated and therefore conducive to 
proliferation.  
 
Targeting GDF6 and BMP signaling in melanoma 
Our patient cohort analyses show that a major fraction of melanomas 
express GDF6 and have an active BMP pathway. Since GDF6 expression is 
correlated with poor patient survival and inhibition of GDF6 leads to cell death, 
targeting this gene or the BMP pathway may prove to be an effective therapeutic 
intervention for melanomas. GDF6 itself is an attractive target since its 
expression is very low or undetectable in most adult tissues (2013). The 
knockout of mouse Gdf6 indicates that it is a non-essential gene, although it is 
necessary for the development of certain joints, ligaments and cartilage (Settle et 
al., 2003). These developmental activities of GDF6 would likely not complicate 
treatment of adult patients with anti-GDF6 therapy, although it is not known 
whether GDF6 inhibition would affect the limited repair of connective tissues that 
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occurs in adults. On the other hand, BMP signaling regulates the function or 
repair of some adult tissues, including muscle, bone and lung (Cai et al., 2012; 
Sartori et al., 2013; Tsuji et al., 2006). Thus, GDF6 inhibition could be more 
specific to melanoma tissue as compared to a broad BMP pathway inhibitor such 
as DMH1, which would block BMP signaling in normal tissues. As a secreted 
molecule, GDF6 inhibition could be accomplished by a variety of means, 
including cell-impermeable therapies. Such therapies could be used in different 
molecular subtypes of melanoma, as cell death caused by GDF6 inhibition does 
not depend on underlying BRAF, NRAS or other driver mutations. Our data do 
suggest that tumors expressing high levels of GDF6 would be particularly 
sensitive to GDF6 inhibition. This elevated expression correlates with GDF6 gene 
amplification, which is present in 38% of melanomas (Akbani R, 2015). However, 
80% of the melanomas we analyzed showed high GDF6 expression, suggesting 
that mechanisms other than amplification can lead to higher expression. 
Ultimately it would be useful to determine if the level of GDF6 expression is 
predictive of therapeutic response to a GDF6 or BMP inhibitor. As indicated by 
the potent activity against xenografts of DMH1 with dabrafenib+trametinib, such 
an inhibitor could be used in conjunction with BRAF inhibitors and other MAPK 
pathway inhibitors to treat this lethal disease. 
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 CHAPTER III 
 
Zebrafish melanoma-derived neural crest signature predicts melanoma 
patient survival   
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INTRODUCTION  
 
Melanomas are highly aggressive skin cancers that arise from pigment-
producing melanocytes. Melanocytes develop from an embryonic tissue-type 
called the NC. The NC is a multipotent tissue type that has a remarkable 
potential to proliferate, migrate and give rise to different cell types. A highly 
complex network of signaling factors orchestrates these processes in the NC. 
Several of these factors are expressed in the NC, and their expression is turned 
off upon terminal differentiation to different lineages. However, tumors originating 
from these lineages, like melanomas, reexpress some of these factors (Bhaskara 
et al., 2012; Gupta et al., 2005; Hohenauer et al., 2013; Kuphal and Bosserhoff, 
2006). It is predicted that expression of these factors endows pro-tumorigenic 
features to these cancer cells.  
 Melanomas have been associated with expression of NC factors that are 
usually not expressed or lowly expressed in the parental melanocytic lineage. 
Analyses of these factors have indicated that pathways specific to the NC can 
play a wide range of pro-tumorigenic roles in melanoma cells. NC factors like 
SOX10 and BRN3a promote tumor cell survival, whereas expression of 
endothelial-to-mesenchyme promoting factors like SNAIL, SLUG and PAX3 
induce migratory behaviors in melanoma cells (Eccles et al., 2013; Hohenauer et 
al., 2013; Shakhova et al., 2015; Shakhova et al., 2012). Recently, studies have 
also shown involvement of neural crest factors like FOXD3 and ZEB1 in 
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resistance to the BRAF and MEK inhibitors in melanomas (Basile et al., 2012; 
Richard et al., 2016). These studies have defined diverse roles for NC factors in 
melanomas. However, there are no known gene signatures that represent the 
existence of NC identities in patient melanomas. Furthermore, whether the 
presence of such a NC gene signature has any prognostic value is also largely 
unknown for patients with melanomas.  
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RESULTS & DISCUSSION 
 
Although roles for NC factors in melanomas have been identified using 
cell-based assays and in animal models, very few studies have investigated 
expression of NC factors in patient melanomas. Moreover, it is unclear whether 
expression of NC factors correlates with clinical features of melanoma patients. 
To test this, we analyzed if expression of NC factors known to be involved in 
melanoma progression correlated with patient survival. Using publically available 
The Cancer Genome Atlas (TCGA) database, we correlated NC factor 
expression with patient survival and found that independently these factors failed 
to predict survival outcome of patients (Table 3.1). Since the roles of NC factors 
in melanomas are multifaceted, we hypothesized that NC identities in melanoma 
can be better represented by a set of NC genes rather than individual factors. 
Therefore we sought to identify such a NC gene set and assess whether such a 
gene signature would show any clinical correlation. 
 In order to seek a melanoma-specific NC gene signature, we used a 
zebrafish model of melanoma that combines melanocyte-specific expression of 
BRAFV600E along with a loss-of-function P53. Melanomas in this model of 
zebrafish initiate from melanocytic cells that have neural crest identities 
(Kaufman et al., 2016). Therefore, we hypothesized that this melanoma model 
would be ideal to obtain a NC gene signature. We isolated melanomas and  
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Gene Hazard Ratio LCL (95%) UCL (95%) Log rank P-value 
SOX10 1.07 0.93 1.23 0.36 
FOXD3 0.98 0.87 1.11 0.73 
SNAI1 0.98 0.9 1.07 0.65 
SNAI2 1.11 0.99 1.25 0.07 
MITF 1.09 0.99 1.21 0.07 
PAX3 1.09 0.97 1.23 0.14 
ZEB1 0.90 1.1 0.78 0.03 
 
Table 3.1: Correlation of neural crest gene expression with overall 
melanoma patient survival 
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scale-associated normal melanocytes from these zebrafish and performed RNA 
sequencing and differential analysis (Figure 3.1A). Pathway analysis of genes 
differentially regulated genes in zebrafish melanomas as compared to normal 
melanocytes showed an enrichment of NC factors, emphasizing the role of NC 
identities in zebrafish melanomas (Figure 3.2B). Since neural crest factors are 
known to act via elevated expression in melanomas, we identified NC genes that 
are upregulated in zebrafish melanomas as compared to normal melanocytes 
and defined a 15-gene NC signature (Figure 3.3C).  
 In assessing this signature, we first tested the presence of this zebrafish 
melanoma-derived NC gene signature in patient melanomas (TCGA database). 
We probed the expression of the gene signature in patient-derived melanomas 
and found that they positively correlate with SOX10 (Figure 3.2A), a factor that 
has been implicated with NC identities in melanoma (Kaufman et al., 2016). 
These results indicate that melanomas arising in this zebrafish model would 
represent NC identity-positive melanomas arising in human patients. These 
results support the use of zebrafish melanoma model to study the subset of 
melanomas that harbor neural crest features. This model could help gain insight 
into tumor mechanisms relating to NC features and provides an ideal model for 
therapeutic targeting of these mechanisms. 
 Next, we wanted to assess whether the NC gene signatures could predict 
melanoma patient survival. After normalizing for age and sex of patients, we 
segregated overall survival of patients based on the average expression of  
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Figure 3.1: Transcriptome analysis of zebrafish melanomas to identify a NC 
gene signature 
(a) Schematic showing isolation of melanoma cells and scale-associated 
melanocytes from Tg(Pmitf:BRAFV600E);p53(lf) zebrafish to perform comparitive 
transcriptome analysis. (b) Pathway analysis with genes differentially regulated in 
zebrafish melanomas as compared to normal melanocytes (minimum overlap ≥ 
10 genes; adjusted P-value < 0.01). (c) Heat map of neural crest genes 
upregulated (≥ 2 fold) in zebrafish melanomas as compared to normal 
melanocytes. 
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Figure 3.2: Correlation of zebrafish-derived NC signature with human 
melanomas 
(a)  GSEA shows that average expression of genes in the NC gene signature 
(excluing SOX10) positively correlates with expression of SOX10 in patient-
derived melanomas. (b) Kaplan-Meier analysis showing overall survival of 
patients with low 15-gene NC signature expression (green line) versus high 15-
gene NC signature expression. The survival outcome has been adjusted for age 
and sex of the patients. Statistical anlaysis was performed with Manter-Cox log 
rank test.  
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the 15-gene NC signature. Patients whose tumors had high expression of this 
15-gene NC signature showed lower survival probability than did patients whose 
tumors had low expression of the signature (Figure 3.2B). Furthermore, the 
expression of this signature had no bias towards the stage of the disease (Figure 
3.3), implying that the signature could independently predict patient survival.  
 Here, we identify a NC gene signature for melanomas that can be used as 
a prognostic marker. These results add to the growing evidence of the 
importance of neural crest programs in melanoma. Drugs like Leflunomide that 
specifically target transcriptional programs common to both, the neural crest and 
melanomas have shown great promise in abrogating tumor growth (White et al., 
2011). Use of this drug in combination with Vemurafenib, a mutant-BRAF 
inhibitor, for treatment of melanomas is currently being tested in clinical trials 
(Kraehn et al., 2001). With further studies, this signature could potentially be 
used to predict response to such treatment modules. 
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Figure 3.3: Correlation of 15-gene NC signature with clinical stage of 
patient melanomas  
(a)  Comparison of15-gene NC signature in ealry stage melanomas (Stage I or II) 
versus late stage melanomas (Stage III or Stage IV). (b) Comparison of 15-gene 
NC signature in primary versus metastatic melanomas. ns, not significant. 15-
gene NC signature was calculated by averaging the log2-transformed expression 
values of the 15 neural crest genes. 
  
a
1
5
-g
e
n
e
 N
C
 s
ig
n
a
tu
re
e
x
p
re
s
s
io
n
 
0
2
4
1
5
-g
e
n
e
 N
C
 s
ig
n
a
tu
re
e
x
p
re
s
s
io
n
 
S
ta
ge
I o
r I
I
S
ta
ge
III
 o
r I
V
ns
0
2
4
P
rim
ar
y
tu
m
or
M
et
as
ta
tic
tu
m
or
ns
Supplementary Figure S1 
b
  
96 
CHAPTER IV 
METHODS 
 
Cell lines and cell culture 
A375, M14, C32 and HEK293T cells (ATCC) were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) and SK-MEL-28, SK-MEL-5 cells (ATCC) 
were maintained in Roswell Park Memorial Institute (RPMI) 1640 media 
supplemented with 10% fetal bovine serum (FBS) and 2 µg/ml Pen Strep (Gibco) 
at 37°C and 5% CO2. Cells cultured at the same time were pooled, counted and 
then seeded in a 10cm dish. Wells/dishes were then subjected to treatment with 
lentiviral vectors. 
 
Lentiviral infection 
Lentiviral infections were performed as described previously (Ceol et al., 2011). 
For stable gene knockdowns, we used pLKO-1 lentiviral vectors to deliver short 
hairpin sequences (shRNAs) (obtained from the RNAi Consortium (TRC)/Broad 
Institute through the UMMS RNAi core facility) specific for GDF6 (GDF6.1: 
TRCN0000141818, target sequence: GCCAAGTGTTACATTGAGCTT; GDF6.2: 
TRCN0000140097, target sequence: GTGTCCATGCTCTCAGACAAA) or 
SMAD1 (SMAD1.1: TRCN0000021781, target sequence: 
CGGTTGCTTATGAGGAACCAA; SMAD1.2: TRCN0000021782, target 
sequence: GCCGATGGACACAAACATGAT) or EGFP (TRCN0000072181, 
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target sequence: ACAACAGCCACAACGTCTATA). Virus was made using a 
second generation lentiviral packaging system in HEK293T cells and quantified 
using a p24 ELISA kit (Clontech). Cells were infected with virus at a multiplicity of 
infection of 2.5 with 8 μg/ml polybrene followed by puromycin selection (2 μg/ml) 
for 2 days in appropriate media. For genetic epistasis experiments with SOX9, 
we used the pGIPZ lentiviral vectors (obtained from Thermofisher Scientific 
through the UMMS RNAi core facility) to deliver shRNAs specific for SOX9 
(V3LHS_396212, target sequence: AGTCGTACTGTGAGCGGGT) or used the 
non-silencing control (target sequence: CTTACTCTCGCCCAAGCGAGAG) 
(Deng et al., 2015). A375 melanoma cells expressing an shRNA targeting GDF6 
or EGFP were treated with virus delivering SOX9 or non-silencing shRNA. The 
viral dosage was determined such that 100% of the cells were EGFP-positive 
and therefore contained the pGIPZ vector expressing either SOX9 or non-
silencing shRNA. For transgene expression, we used Gateway cloning (Life 
Technologies) to insert the GDF6 or SNAI2 ORF (GE life sciences) or 
SMAD1DVD ORF (provided by Takenobu Katagiri, Saitama Medical University, 
Saitama, Japan) into the pLenti CMV Hygro DEST (w117-1) vector (provided by 
Paul Kaufman, University of Massachusetts Medical School, Worcester, USA). 
Infection and monitoring was performed as described (Ceol et al., 2011), except 
that selection was done with 300 ug/ml hygromycin for 10 days. 
 
Mouse xenografts 
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A375 cells stably expressing an EGFP or GDF6 or SMAD1 shRNA and/or empty 
vector or GDF6-expressing vector or SMAD1DVD-overexpressing vector were 
subcutaneously injected into the flanks of 6-8-week-old BALB/c nu/nu female 
mice (Taconic Farms) to produce orthotopic primary tumors. Primary tumor 
growth was monitored every 3 days with calipers, and tumor volume was 
calculated as described previously (Gazin et al., 2007). For GDF6 knockdown, 
SMAD1 knockdown and epistasis experiments with SMAD1DVD overexpression, 
1 x 107 live cells were injected. For GDF6 overexpression experiments and 
epistasis experiments with SOX9 knockdown, 1 x 106 live cells were injected. For 
GDF6 overexpression and GDF6 knockdowns, a representative of two 
independent experiments (n=3 animals per experiment) is shown. For DMH1 
drug experiments shown in Figure 3F, 1 x 106 live A375 cells were 
subcutaneously injected in the flanks of BALB/c nu/nu female mice. Beginning on 
the day cells were injected, mice were injected intraperitoneally with vehicle 
(12.5% 2-hydroxypropyl-β-cyclodextrin) or 25 mg/kg DMH1 in vehicle every other 
day. This experiment was repeated twice and the weighted average of both 
experiments (n=8 animals total) is represented. For drug experiments in Figure 
7D, 1 x 106 A375 cells were subcutaneously injected in the flanks of BALB/c 
nu/nu female mice. Once the tumors volumes reached 75 mm3, groups of mice 
were treated with vehicle, DMH1, dabrafenib+trametinib or a combination of all 
three drugs. DMH1 was administered intraperitoneally in seven day cycles with 
25 mg/kg given twice a day for 5 days and once a day for 2 days. Dabrafenib 
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(300 mg/kg) + trametinib (0.3 mg/kg) were administered by oral gavage once per 
day. The control group received the vehicle 12.5% 2-hydroxypropyl-β-
cyclodextrin intraperitoneally in seven day cycles with 25 mg/kg given twice a day 
for 5 days and once a day for 2 days. Control animals also received 0.5% 
hydroxypropyl methylcellulose once a day by oral gavage. These treatment 
regimens were continued until the end of study or until tumors reached 400 mm3. 
A total of 8 or 9 animals were used in each group.  
 
Zebrafish stocks and husbandry 
Zebrafish were maintained at 28.5°C with a 14 hours ON: 10 hours OFF light 
cycle. Tg(mitfa:BRAFV600E)(Patton et al., 2005), p53(lf)(Berghmans et al., 2005), 
mitfa(lf)(Lister et al., 1999) and gdf6a(lf)(Gosse and Baier, 2009) zebrafish 
strains were used. gdf6a(lf) mutants were generously provided by Dr. Herwig 
Baier, Max Plank Institute of Neurobiology, Martinsried, Germany. AB was used 
as the wild-type strain.  
 
miniCoopR assay 
The miniCoopR assay measuring the effect of gdf6b on melanoma onset in 
zebrafish was performed as previously described (Ceol et al., 2011). For 
miniCoopR-EGFP experiments a weighted average of two independent 
experiments is represented, and for miniCoopR-gdf6b experiments a weighted 
average of four independent experiments is represented. For the embryonic 
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melanocyte rescue analysis, embryos were treated with epinephrine (1 mg/ml) at 
4 days post fertilization to contract pigment to distinguish any overlapping cells, 
and melanocytes were counted manually.  
 
cDNA synthesis and qRT-PCR 
For adult zebrafish, total RNA was extracted from melanoma cells and from 
normal scale-associated melanocytes of Tg(mitfa:BRAF(V600E)); p53(lf); alb(lf); 
Tg(mitfa:EGFP) zebrafish. For isolation of melanoma cells, melanomas were 
dissected, dissociated using Liberase TH treatment and subjected to 
fluorescence activated cell sorting (FACS) to isolate EGFP-positive cells. The 
same protocol was used for normal melanocytes, except dorsal scales from 
zebrafish were plucked to isolate melanocytes. Total RNA from zebrafish 
melanomas and melanocytes was isolated using Trizol-chloroform extraction, 
followed by RNA clean up (Qiagen RNeasy). Total RNA was reverse transcribed 
using the Superscript 2 Reverse Transcriptase kit (Invitrogen).  qRT-PCR with 
SYBR green master mix (Biorad) was performed using the following primers: 
gdf6a F: CTGAGAAACTGGGGCTCAAT, gdf6a R: 
CGACCAGCTCCTCTTTGTCT, gdf6b F: CGTCTAAAGCAGCAAACACC, gdf6b 
R: CCAAAGTGGAGAGTTCAAATGG, actb1 F: CGAGCAGGAGATGGGAACC, 
actb1 R: CAACGGAAACGCTCATTGC. For zebrafish embryos, drug treatment 
was performed as mentioned in Experimental Procedures, except 10µM DMH1 
was used and total RNA was isolated at 20 hpf in the same manner. qRT-PCR 
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was performed using the following primers: mitfa F: 
CTGGACCATGTGGCAAGTTT, mitfa R: GAGGTTGTGGTTGTCCTTCT, tyrp1b 
F: CGACAACCTGGGATACACCT, tyrp1b R: AACCAGCACCACTGCAACTA. 
For A375 human melanoma cells with GDF6 and/or SMAD1DVD modulation, 
total RNA was prepared in the same manner, and qRT-PCR was performed 
using the following primers: ID1 F: CCAACGCGCCTCGCCGGATC, ID1 R: 
CTCCTCGCCAGTGCCTCAG, ID3 F: CTGGACGACATGAACCACTG, ID3 R: 
GTAGTCGATGACGCGCTGTA, SNAI2 F: TGTTGCAGTGAGGGCAAGAA, 
SNAI2 R: GACCCTGGTTGCTTCAAGGA, SOX9 F: 
GTACCCGCACTTGCACAAC, SOX9 R: TCTCGCTCTCGTTCAGAAGTC, MITF 
F: AAACCCCACCAAGTACCACA, MITF R: ACATGGCAAGCTCAGGAC, TRP1 
F: GTAACAGCACCGAGGATGG, TRP1 R: TCCAAGCACTGAGCGACAT, 
GAPDH F: TGCACCACCAACTGCTTAGC, GAPDH R: 
GGCATGGACTGTGGTCATGAG. 
 
Gene set enrichment analysis (GSEA) and pathway analysis 
For GSEA, the enrichment score (ES), normalized enrichment score (NES) and 
familywise error rate (FWER) were calculated based on a running metric, which 
increased when a gene (vertical line in the graphical representation) in the gene 
set was encountered and decreased when one was not. For GSEA of the 
apoptotic pathway gene signature (MSigDB- M10169) (Wu et al., 2002), a rank-
ordered gene list was made with FPKM values from GDF6-overexpressing A375 
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melanoma cells as compared to empty vector control cells or A375 cells 
expressing an shRNA targeting EGFP as compared to GDF6.1 shRNA-
expressing cells. Default parameters of GSEA were used and the Student’s t-test 
was used to calculate significance. For GSEA based on TCGA samples, a rank-
ordered gene list was derived from the expression profiles of 385 melanoma 
samples, using GDF6 expression level as a continuous variable. Default 
parameters of GSEA were used, and Pearson correlation was used to calculate 
significance. Pathway analysis was performed using the WEB-based Gene SeT 
AnaLysis Toolkit (WebGestalt) (Wang et al., 2013a). Default parameters were 
used, except the minimum number of genes for a category was set to 10. 
 
Statistics 
Data are presented as mean ± s.e.m. Differences between groups were 
assessed by a two-tailed Student’s t test, except in Figures 2G, 2H (left), 3G, 5B, 
5C, 6B, 6D, 6F, 6G, 7D and Supplemental Figures S4A, S4B, S6C, S7B, S7G, 
S7I, S8C, S9A, S9B, S9C, S10A-D, S11A, S11C, S11E, and S11F where a one-
way ANOVA test was used (GraphPad Prism 7 software). In Figure 7C, 
Supplemental Figures S1C and S13B a two-tailed Welch’s t test was used 
(GraphPad Prism 7 software) In Figure 3E a two-sample Kolmogorov-Smirnov 
test was used. In Figures 1C, 3C, 4A, 6A and Supplemental Figures 8A and 8B 
we used a family-wise error rate (FWER) P value to account for multiple 
comparisons. For multiple comparisons Dunnett or Bonferroni tests were used as 
  
103 
appropriate. Kaplan-Meier curves were generated using GraphPad Prism 7 
software and the differences between groups were assessed by Wilcoxon rank 
sum analysis for Figures 2A and 2H and by Mantel-Cox log-rank analysis for 
Figure 7B and Supplemental Figure 12. A P value less than 0.05 was considered 
significant. 
 
Study approval 
All zebrafish and mouse studies were performed according to Institutional Animal 
Care and Use Committee (IACUC) guidelines and University of Massachusetts 
Medical School Animal Care Committee protocols. Approval for the tissue 
microarray study was granted by the Brigham and Women’s Partners Human 
Research Committee. Informed consent was not necessary as all samples were 
discardable tissue and deidentified. 
 
Growth curve, clonogenic and soft agar assays 
For growth curves 50,000 live cells were seeded per well in a 6-well tissue 
culture plate on day 0. The numbers of live cells were calculated every day using 
an automated cell counter (Nexcelom Bioscience Cellometer Auto T4) following 
standard procedures. All assays were performed with technical replicates. For 
clonogenic assays, 3,000 live cells were seeded in a 10 cm tissue culture plate. 
After 3 weeks, colonies were fixed and stained using bromophenol blue in 
acetone. ImageJ was used to quantify the number of colonies. In assays with 
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DMH1 treatment, control or DMH1-containing media was replaced every other 
day. For soft agar assays a 0.5% bottom layer  (1:1 with 1% agar and 2XDMEM 
with 20% FBS) and a 0.3% top layer (1:1 with 0.6% agar and 2XDMEM with 20% 
FBS) were used. 3,000 live cells per well of a 6-well tissue culture plate were 
added in the top layer. Media was added initially then replaced every 3 days. 
After 3 weeks, colonies were stained with nitroblue tetrazolium chloride overnight 
at 37°C. Once stained, individual wells were photographed, and ImageJ was 
used to count the number of colonies. All these assays were done in triplicate, 
and experiments were repeated at least twice. 
 
Cell death assays 
A375 melanoma cells after stable knockdown and/or overexpression were 
stained for Annexin V and 7-AAD (BD Pharmingen PR Annexin V Apoptosis 
Detection kit) as per manufacturer’s instructions, followed by flow cytometry 
using a FACSCalibur instrument (BD Biosciences). Caspase3/7 activity was 
measured using the Caspase-Glo 3/7 assay (Promega) as per manufacturer’s 
instructions.  
 
Animal experiments 
All animal protocols were approved by the UMMS Institution Animal Care and 
Use Committee (A-2016, A-2171). Mice were randomly allocated to individual 
experimental groups. No blinding was done as animal groups were identified by 
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tagging and cage labeling. Animals were excluded, according to pre-established 
criteria, if the tumor volume reached >1,000 mm3; if tumor size or location 
affected the mobility or general health of animal, the animal was euthanized and 
excluded from the experiment or the complete experiment was terminated.  
 
Antibody production 
Antibodies recognizing Gdf6b were generated by injecting a glutathione S-
transferase-tagged gdf6b, GST-gdf6b, into two guinea pigs. Antibodies were 
validated by comparing reactivity of pre- and post-immune sera to bacterially-
expressed GST-gdf6b. Results from one of the antibodies are shown. 
 
Immunofluorescence 
For adults, dorsal scales bearing normal melanocytes or melanomas were 
plucked from anesthetized zebrafish. After fixation, scales were bleached of 
melanin pigment to visualize fluorescence after staining. Scales were incubated 
with primary antibody (Gdf6b (1:250), Mitfa (1:250)) overnight. Subsequently the 
scales were washed, incubated in appropriate secondary antibodies (Jackson 
Labs), incubated with DAPI, mounted on slides with Vectashield (Vectorlabs), 
and visualized using confocal fluorescence microscopy.  
 
Immunoblotting 
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Protein extracts were separated on 12% SDS-PAGE gels. Blots were probed 
with primary antibodies (GDF6 (Sigma PRS4691; 1:1000), phospho-SMAD1/5/8 
(Cell Signaling 13820; 1:1000), SMAD1 (Cell Signaling 9743; 1:500), Total 
SMAD1/5/8 (Santa Cruz sc-6031-R; 1:1000), FLAG (Sigma F3165, 1:2000), 
SOX9 (Cell Signaling 82630S; 1:1000), GAPDH (Abcam 8245; 1:2000)) 
overnight at 4°C, washed five times in TBS plus 0.1% Tween (TBST) and then 
incubated with the appropriate HRP-conjugated secondary antibody (Jackson 
Labs) for 1 hour at room temperature. Membranes were washed five times in 
TBST and visualized on autoradiography film after incubating with ECL reagent 
(Supersignal West Pico or Supersignal West Femto; Thermo Scientific). 
 
Immunohistochemistry (IHC) and TUNEL staining 
From mouse xenografts, formalin-fixed, paraffin-embedded tissues were 
processed to obtain 5µm sections. Sections were stained with H&E, cleaved 
Caspase-3 (Cell signaling 9664; 1:100), Ki-67 (Dako M7240; 1:100) and 
evaluated. TUNEL staining was performed on sections using the In Situ Cell 
Death Detection kit (Roche) as per manufacturer’s protocol. The numbers of 
TUNEL-positive or cleaved Caspase-3-positive or Ki67-positive cells were 
counted manually and the total number of cells in each field was calculated using 
ImageJ software. 
Individual patient melanoma and tissue microarray cores consisted of 5 µm 
sections of formalin-fixed, paraffin-embedded tissues. Slides were first 
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deparaffinized with two changes of xylene, and rehydrated with changes of 
decreasing concentrations of alcohols, then rinsed in distilled water. Antigen 
retrieval was carried out with 0.01M citrate buffer at pH 6.0, or 0.001M EDTA at 
pH 8.0.  Slides were heated in a 770W microwave oven for 14 minutes, cooled to 
room temperature, and rinsed in distilled water. The sections were first blocked 
for endogenous non-specific protein and peroxidase activity with an application of 
Dual Endogenous Block (Dako) for 10 minutes, followed by a buffer wash, 
followed by staining with antibodies recognizing GDF6 (Sigma PRS4691; 1:1000) 
and p-SMAD1/5/8 (Cell signaling 9664; 1:100) for 30 minutes. Staining with a 
second antibody recognizing GDF6 (Sigma HPA045206; 1:100) yielded 
concordant results. For negative controls, non-immune immunoglobulin G (a 
cocktail of Mouse Whole IgG and Rabbit Whole IgG (Pierce antibodies 31204 
and 31207, respectively; both 1ug/ml)) staining was used. Following a buffer 
wash, sections were incubated with the EnVision+ Dual Link (Dako) detection 
reagent for 30 minutes. The sections were washed, and treated with a solution of 
diaminobenzidine and hydrogen peroxide (Dako) for 10 minutes, to produce the 
visible brown pigment.  After rinsing, a toning solution (DAB Enhancer, Dako) 
was used for 2 minutes to enrich the final color. The sections were 
counterstained with hematoxylin, dehydrated, and coverslipped with permanent 
mounting media. Positive signal was defined as dark brown staining. Scant, or 
fine granular background staining, or no staining was considered negative.  
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Zebrafish formalin-fixed, 5mM EDTA treated, paraffin-embedded tissues were 
processed to obtain 5µm transverse sections. Sections were stained for H&E and 
as mentioned above with p-SMAD1/5/8 (Cell Signaling 9511; 1:150) and 
coverslipped with permanent mounting media. TUNEL staining was performed on 
sections with fluorescein-dUTP using In Situ Cell Death Detection kit (Roche) as 
per manufacturer’s protocol. For TUNEL staining, sections were bleached in 
bleaching solutions (3% hydrogen peroxide 1% Potassium hydroxide) to remove 
the melanin pigment. The numbers of TUNEL-positive were counted manually 
and the total number of cells (DAPI positive) in each field was calculated using 
ImageJ software. 
 
IHC scoring 
For both the UMass patient cohort and the tissue microarray, a modified visual 
semi-quantitative method was used. Sections were scored for immunointensity 
(0-4) and immunopositivity (0-3), which were then multiplied. For the UMMS 
patient cohort, scoring was done by C.J.C. and A.M.V., and the scores were 
averaged. Scores were verified by A.D. For the tissue microarray cohort, scoring 
was conducted independently by C.L. and C.B.F.G. and the scores were 
averaged. Sections with scores less than or equal to four were binned into the 
low or no staining group and sections with scores greater than four were binned 
into the high staining group.  
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in situ hybridization 
Embryos were grown at 28.5°C until the desired stage, then dechorionated and 
fixed in 4% PFA/PBS for 24 hours at 4°C. Following fixation, embryos were 
dehydrated in methanol and stored at -20°C. For in situ hybridization, embryos 
were rehydrated, permeabilized with proteinase K, and hybridized with 
digoxigenin-labeled probes in hybridization solution (1:100) overnight at 68°C. 
Probe mixes were removed, embryos were washed in TBST, and then incubated 
in blocking solution (0.5% Roche Blocking Reagent in TBST) at room 
temperature. Subsequently the embryos were incubated in anti-digoxigenin-AP 
conjugated antibody (Roche) diluted in blocking solution (1:400) overnight at 4°C. 
Following antibody incubation, the embryos were washed in TBST, and the RNA 
probes were visualized by incubation in NBT-BCIP solution (NBT-BCIP stock 
solution from Roche, diluted 1:200 in TBST with 50 mM MgCl2). After staining, 
embryos were washed in PBS and stored in 4% PFA/PBS at 4°C, then mounted 
3% methylcellulose for imaging. 
 
Quantifying melanocyte numbers in embryonic zebrafish 
Zebrafish embryos were injected with miniCoopR-EGFP, miniCoopR-gdf6a or 
miniCoopR-gdf6b at the single-cell stage and then grown at 28.5°C. At 4 days 
post-fertilization, embryos were visualized under a light microscope to identify 
ones that had a chimeric pattern of melanocyte rescue. Additionally, the number 
of melanocytes per rescued embryo was counted manually.  
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Chromatin immunoprecipitation (ChIP) sequencing and analysis 
ChIP was performed using the Simple ChIP Plus Enzymatic Chromatin IP kit as 
per manufacturer’s instructions (Cell Signaling 9001) with the p-SMAD1/5/8 
antibody (Cell Signaling 11971; 1:100). ChIP-DNA from A375 melanoma cells 
expressing an shRNA targeting GDF6, GDF6.1 or EGFP or a 2% input control 
was used for library preparation using the TruSeq ChIP Library Prep Kit for ChIP-
Seq (Illumina). Fastq files were aligned to the human reference genome 
(ENSEMBL GRCH37) by Bowtie (version 1.0.0) (Langmead et al., 2009) allowing 
uniquely mapped reads and removing PCR duplicates. For aggregation plotting, 
aligned reads were processed in HOMER (Heinz et al., 2010) using 
annotatePeaks to bin the regions of interest in 20-bp windows resulting in 
average enrichment with normalized reads for all genes. MACS2 (version 
2.1.1.20160226) (Feng et al., 2012) was used for peak calling. Peaks with a false 
discovery cutoff of 1% were used. The alignment files were converted to 
bedGraph files and loaded as custom tracks in the UCSC genome browser to 
visualize regions of interest. ChIPpeakAnno (version 3.5.12) (Zhu et al., 2010) 
was used to visualize and compare the overlapping pSMAD1/5/8 peaks for 
genes bound by pSMAD1/5/8 in wild-type and GDF6 knockdown A375 cells. 
 
aCGH probe design 
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We custom designed the G3 array format of 2x400K probes for the Zebrafish 
ZV9 genome assembly using Agilent’s eArray (eArray ID 036041). The array has 
398426 unique probes covering 97% of the zebrafish genome (based on Zv9 
assembly). The probes are 60 bases long and are spaced across the genome 
with an average separation of 3550 bases.  
 
aCGH, JISTIC analysis and comparative analysis 
aCGH was performed as per Agilent’s array-based genomic DNA hybridization 
protocol. Briefly, genomic DNA was extracted from zebrafish melanomas or a 
normal region of the same fish using the Qiagen DNeasy Blood and Tissue kit. 5 
µg of tumor or matched normal gDNA was fragmented to 200-500bp by 
sonication (Covaris S220R High Performance Sample Preparation Ultrasonicator 
System 220x S), labeled in a random-primed reaction using Cy5-dCTP or Cy3-
dCTP, respectively, and hybridized in Agilent’s hybridization buffer with Cot1 
DNA (1mg/ml) at 65°C overnight. Arrays were then washed, and Cy5 and Cy3 
signals were measured using an Agilent G2565 Microarray Scanner. Raw data 
was generated from scanned images with the Agilent Feature Extraction software 
(v10.7). Raw values were normalized using the Agilent Genomic workbench and 
copy number alterations were detected. The JISTIC algorithm was used in limited 
peel-off mode to calculate significantly altered regions, and peak calling was 
done using a q-value cut-off of 0.25. Gene-based JISTIC G-scores and –log10 
transformed q-values are represented using the Circos package (Krzywinski et 
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al., 2009). For representation of data, the G-score scale for amplifications was 0 
(minimum) and 1550 (maximum), and for deletions it was 0 (minimum) and 2150 
(maximum). The log10-transformed q-value scale for both amplifications and 
deletions was 0 (minimum) and 11 (maximum). For human melanomas, copy 
number data was downloaded from Tumorscape (Beroukhim et al., 2010; Lin et 
al., 2008), and JISTIC analysis was conducted as described above. Genes from 
within peaks were pooled to define species-specific sets of recurrently amplified 
genes. Human orthologs of zebrafish genes were determined using Ensembl 
(Collins et al., 2012; Howe et al., 2013) and supplemented by performing BLAST 
(Altschul et al., 1990). Recurrently amplified zebrafish and human genes, as 
determined by JISTIC, were compared to find the overlapping set of commonly 
amplified genes.  
 
cDNA amplification and microarray analysis 
Total RNA was extracted and prepared from melanoma cells and from normal 
scale-associated melanocytes of Tg(mitfa:BRAF(V600E)); p53(lf); alb(lf); 
Tg(mitfa:EGFP) zebrafish as described above. Total RNA was amplified using 
the Nugen Ovation RNA Amplification system V2 as per manufacturer’s protocol. 
For microarrays, amplified cDNA was hybridized to a 385K microarray 
(NimbleGen 0711105Zv7EXPR) as per manufacturer’s protocol. Briefly, amplified 
cDNA from melanomas and melanocytes were labeled with Cy3 independently, 
hybridized to the microarray, washed and scanned with a GenePix 4000B 
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Scanner. Images were analyzed and normalized using NimbleScan software, 
and differentially expressed genes were identified.  
 
Massively parallel RNA sequencing 
For zebrafish melanomas and melanocytes, total RNA was isolated as described 
above and libraries were prepared using the TrueSeq Stranded mRNA Library 
Prep Kit as per manufacturer’s protocol (Illumina). FASTQ files were analyzed 
using FASTQC v0.10.1(S, 2010) to ensure uniform read quality (phred>30). 
Paired-end reads were aligned to the zebrafish genome using STAR v2.3 (Dobin 
et al., 2013) (Zv9). The mapped reads were counted using htseq-count (v0.6.0, 
parameters –t exon) (Anders et al., 2015) and gene models from the Ensembl 
transcriptome (Howe et al., 2013). Analyses of differential gene expression were 
performed using DESeq2 (Ritchie et al., 2015). Orthology to human genes was 
determined using Ensembl (Collins et al., 2012; Howe et al., 2013) and 
supplemented by performing BLAST (Altschul et al., 1990). The heatmap of BMP 
pathway genes (REACTOME_SIGNALING_BY_BMP; MSigDB (Broad Institute)) 
was created using human orthologs of differentially expressed BMP pathway 
genes. The fish orthologs of human genes represented are SMAD5=smad5, 
SMAD4=si:dkey-239n17.4, ACVR2A=acvr2a, ACVR2B=acvr2b, 
BMPR1A=bmpr1aa, FSTL1=fstl1b, SMAD7=smad7, BMPR2=bmpr2a, 
SMURF2=smurf2, SMAD6=smad6b, ZFYVE16=zfyve16, SKI=skib, 
GREM2=grem2, SMURF1=smurf1, UBE2D1=ube2d1, CER1=dand5, NOG=nog, 
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BMP2=bmp2b, BMPR1B=bmpr1bb. For A375 human melanoma cells with GDF6 
and/or SMAD1DVD modulation, total RNA was isolated and libraries prepared as 
described above. Prepared libraries were sequenced using Illumina Hiseq 
technology (NY Genome Center). FASTQC v0.10.1 (S, 2010) was used on the 
FASTQ sequences for the A375 samples to generate sequence quality reports. 
Data were analyzed using two different bioinformatics pipelines. In the first 
pipeline, reads were aligned to the human reference genome (Ensembl GRCh37) 
using Bowtie2 (v 2-2.1.0) (Langmead and Salzberg, 2012) and Tophat2 (v 2.0.9) 
(Kim et al., 2013). Samtools (v 0.0.19) (Li et al., 2009) and IGV (v 2.3.60) 
(Thorvaldsdottir et al., 2013) were used for indexing the alignment files and 
viewing the aligned reads, respectively. Gene expression was quantitated as 
fragments per kilobase of exon model per million mapped fragments (FPKM) 
using Cufflinks (v 2.2.0) (Trapnell et al., 2012). Differentially-expressed genes 
were identified using the Cufflinks tools (Cuffmerge and Cuffdiff). cummeRbund 
(v 2.4.1) (Trapnell et al., 2012) was used to assess replicate concordance. In the 
second pipeline, reads were mapped against the human reference genome 
(Ensembl GRCh37) using the aligner STAR (v 2.4.2a), and gene level counts of 
uniquely mapped reads were obtained using htseq-count (v 0.6.1) (Anders et al., 
2015). Differential expression analysis was performed using DESeq2 (Love et al., 
2014) for each pairwise condition using a p-adj threshold of 0.05. The FPKM-
based method and the counts-based method generated concordant results. 
Analyses using the FPKM-based method have been represented in results.  
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Human melanocyte and melanoma transcriptome analysis 
Three hundred and eighty-five human RNA-seq samples were downloaded from 
the Cancer Genomics Hub (CGHub) (https://cghub.ucsc.edu) using GeneTorrent 
(v 3.8.5a) (Wilks et al., 2014). The RNAseq TCGA dataset is comprised of three 
sample types: 302 metastatic melanoma samples, 82 primary melanomas, and 1 
solid tissue normal (2015). For the normal melanocyte datasets, two RNAseq 
samples were downloaded from the Short Read Archive (SRA) 
(https://www.ncbi.nlm.nih.gov/sra/; accession codes: SRR522118, 
SRR522119)(Barrett et al., 2013) and two from the ENCODE project 
(https://www.encodeproject.org/; experiment: ENCSR000CUQ) (2012). The 
datasets downloaded from TCGA, SRA and ENCODE were aligned to the human 
reference genome (Ensembl GRCh37) and analyzed using the FPKM-based 
method described above. 
 
The accession number for the RNAseq, ChIPseq and gene expression 
microarray datasets reported in this paper is GEO: GSE83400 
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CHAPTER V 
FINAL SUMMARY AND DISCUSSION 
  
 
Summary 
 This study (1) used a cross-species comparative genomics approach with 
zebrafish melanoma to identify the novel melanoma oncogene GDF6, (2) defined 
the a role of GDF6-induced BMP signaling in inhibiting MITF and SOX9 to 
maintain melanoma cells undifferentiated and alive, (3) reported the clinical 
relevance of GDF6 expression in patients with melanoma, and (4) generated a 
prognostic NC identity for melanomas. 
 In the first part, a comparative genomic approach was used on human and 
zebrafish melanomas to identify cancer genes dysregulated by CNVs. By 
integrating transcriptome analysis, I identified GDF6 as a recurrently amplified 
and transcriptionally upregulated melanoma oncogene. In zebrafish, the 
overexpression of a GDF6 ortholog accelerated melanoma onset, whereas the 
loss of an ortholog delayed disease onset, indicating the role of GDF6 in tumor 
initiation. In established human melanoma cell lines and mouse xenografts, 
GDF6 overexpression promoted tumor growth, whereas its knockdown 
abrogated growth. By using mechanistic analysis, I observed that GDF6 acts via 
the BMP-SMAD1 signaling axis to invoke trunk NC identity in melanoma cells. As 
a part of this signaling axis, GDF6-activated BMP signaling repressed the 
melanocyte differentiation gene MITF and the proapoptotic melanoma gene 
SOX9, aiding the melanoma cells in remaining undifferentiated and alive. During 
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the analysis of the clinical relevance of GDF6 expression in patients with 
melanoma, I identified GDF6 expression as a prognostic indicator of lymph node 
metastasis, which was inversely correlated with melanoma patient survival. 
During the identification of the role of GDF6 in melanomas, I also noted a novel 
role of GDF6 in regulating melanocyte development. Although the 
overexpression of gdf6 orthologs reduced the number of differentiated 
melanocytes, the loss of gdf6a caused an evident increase in the number of 
melanocyte. Taken together, these findings suggest that developmental functions 
of GDF6 and BMP signaling are reestablished in melanomas to promote tumor 
initiation and maintenance. 
 In the second part, the transcriptome data from zebrafish tumors were 
exploited further to generate a prognostic NC signature for melanoma. Compared 
with normal melanocytes, differentially regulated genes in zebrafish melanomas 
are enriched for NC pathway genes, indicating the activation of NC identities in 
these melanomas. By using this transcriptome data, I generated a 15-gene NC 
gene signature. This gene signature correlated with the expression of SOX10, a 
previously defined NC marker in human melanoma. Patients with melanomas 
having a high expression of this NC gene signature had low overall survival. 
These analyses indicate the clinical relevance of NC identities in melanomas, 
and also establish, for the first time, a prognostic NC gene signature for 
melanomas. 
  
118 
 Overall, this study emphasizes the importance of NC identities in 
melanoma and identifies a new signaling pathway that establishes these 
identities in tumor cells. In addition to providing insight into a fundamental 
process of cancer biology, this study provides new targeting opportunities for 
melanoma therapy. 
 
Comparative Genomics Using Zebrafish as a Gene Discovery Tool 
 Several fundamental aspects of cancer biology have been revealed by 
using zebrafish cancer models, particularly through comparative genomics (Lam 
and Gong, 2006; Zhang et al., 2013; Zhang et al., 2010). Since the advent of 
next-generation sequencing, several cancer genomes have been 
comprehensively analyzed and consequently several tumor-associated genetic 
alterations have been identified. Functional analysis of these aberrations to 
identify their role in tumorigenesis has been a major focus. Comparative 
oncogenomics using zebrafish has aided in identifying such driver alterations and 
their roles in tumorigenesis. 
In this study, I used the zebrafish melanoma model to identify driver genes 
dysregulated by the virtue of CNVs. In human melanomas, approximately 10% of 
the genome undergoes recurrent CNVs (Beroukhim et al., 2010; Lin et al., 2008). 
In CNV regions, most genes are predicted to be random passengers, which alter 
because they are located next to the drivers. I predicted that the evolutionary 
divergence between humans and zebrafish (of approximately 420 million years) 
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would frequently place orthologous driver genes next to different set of 
neighboring genes in each species because of the extensive genomic 
reorganization present between these species (Catchen et al., 2011). To test this 
rationale and identify potential melanoma oncogenes, I compared human and 
zebrafish melanoma copy number amplifications. I assumed the copy number 
amplification mechanism is conserved between human and zebrafish melanomas 
on the basis of the following factors: First, known melanoma oncogenes, such as 
SETDB1, TERT, and MYC, are amplified in human melanomas as well as 
zebrafish melanomas. Second, genome-wide comparisons demonstrated that the 
number of genes commonly amplified in melanomas of both species were 
incidentally much higher than expected. Finally, previous studies have indicated 
that zebrafish melanomas have a low number of DNA base substitution 
mutations, unlike human melanoma (Yen et al., 2013). The current study also 
revealed extensive CNVs in zebrafish melanomas that significantly overlapped 
with the CNV regions identified in my analysis. Taken together, these findings 
suggest that zebrafish melanomas are mostly driven by oncogenes located in 
recurrently amplified regions of the genome, and comparative analysis with 
human melanoma may aid in elucidating novel oncogenes. 
To identify these oncogenes, I next integrated the transcriptome data of 
zebrafish melanomas with comparative copy number amplification analysis. The 
use of zebrafish model for analyzing gene expression of melanomas has a 
unique advantage. Most gene expression studies for melanoma have used either 
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skin sections or transformed melanocyte cell lines as controls to identify 
differentially regulated genes. In this study, I compared gene expression of 
melanoma cells with primary melanocytes directly obtained from zebrafish by 
using Tg(mitfa:EGFP) transgenic zebrafish, the melanocytes of which were 
labeled with EGFP. By using the transcriptome data from zebrafish melanomas 
and melanocytes, I found 128 genes that were not only amplified but also 
transcriptionally upregulated at least 2-fold in the melanomas of both species. 
Among these genes, I focused on GDF6 because of its expression in the NC, an 
embryonic tissue that gives rise to melanocytes. However, because the list 
identified in this study may contain several other melanoma oncogenes, further 
functional analysis is required to reveal the driver genes. 
I also compared copy number deletions in zebrafish melanomas with 
those in human melanomas. Unlike amplifications, the number of genes 
commonly deleted in melanomas of both species were incidentally much lower 
than expected (Figure 4.1). I speculated that this lack of conservation in copy 
number deletions across species could be due to the duplication event that 
occurred in the teleost lineage, causing approximately 40% of human genes to 
have two zebrafish paralogs. Because the deletion of both paralogs of a tumor 
suppressor gene may be required for complete inactivation of the pathway, this 
loss-of-function mechanism may not be opted by zebrafish melanomas. Among 
the 72 commonly deleted genes, only 16% had two zebrafish paralogs compared  
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Figure 4.1: Genes deleted in human and zebrafish melanomas 
Venn diagram of orthologous genes significantly deleted in human and zebrafish 
melanomas from a total of 10380 human-zebrafish gene pairs (hypergeometric 
test, P-value: 4.0e-22). 
  
  
122 
with the expected 40%. Nevertheless, some of these commonly deleted genes 
are potential tumor suppressors; functional analysis using these genes may aid 
in inferring their role in melanomagenesis. 
 
BMP Signaling in Melanoma 
BMP Signaling Invokes an Undifferentiated NC Identity in Melanomas 
In several cancers, a low degree of differentiation is correlated with 
increased tumor initiation capability of transformed cells. A hallmark study linking 
cell differentiation and tumor initiation was performed by the Petrenko lab, 
wherein they used a conditional mouse model to express oncogenic KRASG12D in 
the pancreas and traced the cellular and molecular changes that occurred during 
different transformation stages (Ischenko et al., 2013). The authors noted that 
activated KRASG12D rendered plasticity to differentiated cells, which acquired 
stem cell-like features and transformed into neoplastic cells. Another study found 
cellular dedifferentiation and awakening of stem cell-like features to be involved 
in the initiation of intestinal tumors (Schwitalla et al., 2013). In these tumors, the 
Wnt pathway promotes dedifferentiation-induced tumor initiation. The Wnt 
pathway regulates the fate specification of the intestinal stem cell pool (Tian et 
al., 2016), and this function is potentially invoked during the early stages of 
tumorigenesis. 
In melanomas, embryonic identities have been implicated in tumor 
initiation (Boiko et al., 2010; Kaufman et al., 2016), but the mechanisms involved 
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in regulating these embryonic identities are largely unknown. In the present 
study, I demonstrated that GDF6 promotes melanoma initiation, potentially by 
inducing embryonic NC identities. In zebrafish, gdf6b overexpression accelerates 
melanoma onset, whereas its loss delays the onset, indicating that GDF6 is 
important during tumor initiation in zebrafish. GDF6 regulates an NC identity in 
melanoma cells. Thus, I speculated that the cell-of-origin for zebrafish 
melanomas is an undifferentiated melanocytic cell that has adopted an 
embryonic identity. Corroborating this hypothesis, I reported that GDF6 can 
regulate the differentiation of the melanocyte lineage. During normal 
development, the overexpression of gdf6 orthologs reduced the number of 
differentiated melanocytes in zebrafish embryos, whereas the loss of gdf6a 
caused an evident increase in the number of melanocytes in adult zebrafish, thus 
suggesting that GDF6 inhibits melanocyte differentiation. In human melanoma 
cells, GDF6 directly represses MITF and SOX9, both of which are regulators of 
melanocyte and melanoma differentiation. Thus, GDF6 potentially acts through 
BMP signaling to suppress differentiation signaling in melanocytes, leading to the 
expression of NC factors that induce dedifferentiation and promote tumor 
initiation. In the absence of GDF6, zebrafish develop fewer melanomas; these 
melanomas are highly differentiated and potentially less aggressive. 
The experiments performed in this study determined the role of GDF6 and 
BMP signaling in melanoma initiation in a zebrafish model; however, identifying 
similar mechanisms in a mammalian setting is essential. Such studies are 
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challenging in part because of the lack of available NC reporters for assessing 
changes in the cellular identities of mammalian melanoma models. However, 
here, I detected GDF6 and active BMP pathway in a majority of the melanomas 
(approximately 80%). Moreover, patients with primary melanomas containing 
higher GDF6 levels had an increased likelihood of metastasis and experienced 
shorter survival compared with patients with melanomas containing no or lower 
levels of GDF6. On the basis of these findings, I predicted that even in humans, 
GDF6 is important during the early stages of melanomagenesis and is a 
prognostic predictor of tumor aggressiveness. 
 
BMP Signaling Promotes Melanoma Cell Survival 
 Bernard Weinstein coined the term “oncogene addiction,” which refers to 
the dependency of a cancer on the continued activity or expression of a particular 
oncogene (Weinstein, 2002). In this model, an oncogene provides aberrant 
proproliferative or prosurvival benefits, specifically to the tumor cells and not to 
the corresponding normal tissue. The tumors cannot sustain the loss of this 
oncogene. The biological significance and clinical impact of this model has been 
exemplified by several reports, such as KIT mutations in gastrointestinal stromal 
tumors, EGFR mutations in non–small-cell lung cancers and BCR-ABL 
translocations in acute myeloid leukemia (Demetri et al., 2002; Kantarjian et al., 
2002; Lynch et al., 2004; Paez et al., 2004; Xu et al., 2014). In the present study, 
I observed that melanoma-specific expression of GDF6, either by amplification or 
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transcriptional upregulation, provides prosurvival signals to tumors cells, whereas 
its loss abrogated tumor growth. Thus, the GDF6-expressing melanoma cells are 
addicted to GDF6 activity. 
The potential of GDF6 and BMP signaling to promote melanoma cell 
survival is owing to its ability to regulate SOX9 and SOX10. In melanomas, 
SOX10 is a prosurvival factor, whereas SOX9 is a proapoptotic factor; these 
factors antagonistically crossregulate each other (Shakhova et al., 2015; 
Shakhova et al., 2012). On the basis of gene expression analysis, I noted that 
that GDF6 induces SOX10 expression and represses SOX9 expression, a 
pattern of regulation promoting tumor cell survival. Whether GDF6-activated BMP 
signaling regulates one or both the factors directly requires elucidation. 
According to the current ChIPseq data, GDF6-dependent phosphoSMAD1/5/8-
binding peaks at distal regions upstream of SOX9, thus suggesting direct 
regulation. In the SOX10 promoter, phosphoSMAD1/5/8 peaked, but the binding 
was not abrogated by GDF6 knockdown. Thus, I speculated that GDF6 promotes 
melanoma cell survival by directly repressing SOX9 expression and indirectly 
regulating that of SOX10. 
  
Role of BMP Signaling in Melanocyte Development 
 Several studies have investigated the roles of known developmental 
factors in cancer progression (Gupta et al., 2005; Mack et al., 2016; Maguire et 
al., 2015; Wong et al., 2015). Given the role of GDF6 and BMP signaling in 
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regulating differentiation and NC identity within melanomas, I hypothesized that 
GDF6 have a developmental role during melanocyte development. 
A conglomerate of transcription factors orchestrates melanocyte 
differentiation; in melanomas, GDF6-activated BMP signaling regulates several 
of these factors. Through mathematical modeling and in vivo analysis in 
zebrafish embryos, the Kelsh lab reported a gene regulatory network for 
melanocyte differentiation (Greenhill et al., 2011). According to this model, 
orthologs of MITF and SOX9 (mitfa and sox9b, respectively) are critical for the 
initiation of melanocyte differentiation. GDF6 and BMP signaling repress both of 
these factors in human and zebrafish melanomas. Thus, the ability of GDF6 to 
inhibit melanocyte differentiation in embryos may be resulting from its potential to 
repress mitfa and sox9b expression during zebrafish development. The 
expression of GDF6 orthologs in zebrafish during this time further supports the 
role of this pathway in blocking melanocyte differentiation. GDF6 orthologs are 
expressed in the NC and adjacent tissues; however, during melanocyte 
differentiation, their expression is turned off, potentially enabling mitfa and sox9b 
expression and thereby initiating melanocyte differentiation. Zebrafish with loss-
of-function gdf6a have a relatively higher number of melanocytes, potentially 
because of precocious differentiation. By contrast, in animals with forced 
expression of gdf6a or gdf6b in the melanocyte lineage, I noted a significant 
reduction in the number of differentiated melanocytes, potentially because of 
prolonged repression of mitfa and sox9b expression. 
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The role of BMP signaling during NC lineage segregation is potentially 
reiterated in NC-derived cancers. Tumors originating from the NC lineage adopt 
features of the NC (Maguire et al., 2015); however, the mechanisms involved in 
the establishment of these embryonic identities remain unclear. In this study, I 
demonstrated that the reawakening of NC identities in melanomas is regulated 
by BMP signaling and predicted that this ability of BMP signaling is due to its role 
in inhibiting differentiation of melanocyte lineage from the NC. Studies have 
indicated that BMP signaling promotes the differentiation of the NC into neurons 
and glia (Gajavelli et al., 2004; Goldstein et al., 2005; Saito et al., 2012; 
Schneider et al., 1999). Notably, in neuroblastomas and glioblastomas (tumors 
arising from neuronal and glial cells, respectively), BMP signaling promotes 
tumor differentiation and suppresses cancer initiation and growth (Du and Yip, 
2010; Lee et al., 2008; Piccirillo et al., 2006). Therefore, I predicted that BMP 
signaling has contrasting roles in glioblastomas and neuroblastomas compared 
with those in melanomas and that this role depends on the activity of BMP 
signaling during differentiation of the NC into these specific lineages. 
 
Clinical Relevance of This Study 
Importance of GDF6 Expression in Patients with Melanomas 
 Melanoma therapeutics has considerably advanced in the last decade; 
however, many patients do not respond to current therapies. The current study 
provided a novel target for therapeutic targeting of melanomas. In two 
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independent patient cohorts, GDF6 expression was noted in a majority of 
melanomas (approximately 80%). Furthermore, GDF6 is critical for melanoma 
cell survival because inhibition of this pathway led to tumor cell death. Moreover, 
the prosurvival role of GDF6 is potentially independent of the underlying driver 
mutations. Taken together, these findings indicate that approaches targeting 
GDF6 and BMP pathway components may have therapeutic benefits. 
Several approaches can be used for targeting this pathway in melanomas. 
Here, I performed a proof-of-principal study to demonstrate that targeting BMP 
signaling by using a small molecule inhibitor DMH1 could reduce tumor growth in 
vivo. However, in future, targeting GDF6 ligand, rather than the pleotropic BMP 
pathway, would be ideal. As previously mentioned, GDF6 expression in adult 
tissues is limited to the regions of bone repair. Therefore, GDF6-targeting 
strategies may have a lower toxic effect than anti-BMP targeting strategies 
would. Moreover, GDF6 is a secretory protein; this enables the use of non–cell-
permeable strategies to target this factor. 
The use of GDF6 targeting drugs may be therapeutically beneficial when 
used alone or in combination with BRAF and MAPK pathway inhibitors. First, the 
analysis of TCGA melanomas demonstrated that in melanomas, GDF6 
expression is independent of driver mutations, such as those is BRAF and 
NRAS. Second, the prosurvival role of GDF6 signaling is independent of BRAF 
or NRAS mutations, and GDF6 loss results in cell death in MeWo melanoma 
cells (BRAF and NRAS wild-type). Therefore, the use of anti-GDF6 strategies 
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may function independent of current targeted strategies. However, the use of 
GDF6-targeting strategies can also be used to further bolster the antitumor 
effects of BRAF and MAPK pathway inhibitors. 
 
Importance of NC Identities in Patients with Melanomas 
 Although melanomas can adopt NC identities, the clinical significance of 
these identities remains unknown. The expression of several NC factors, such as 
SOX10, FOXD3, TWIST, and SNAIL, has been observed in patients with 
melanomas; however, no study has revealed the prognostic outcome of 
melanomas expressing these factors. I noted that the RNA expression of NC 
factors—which have been implicated in melanoma progression—cannot 
independently predict melanoma patient survival. Because changes in cellular 
identity involve a global gene expression shift, I predicted that NC identities could 
be best defined by a set of NC genes. 
 We have now used zebrafish melanomas to identify such an NC gene 
signature. Zebrafish melanomas initiate from melanocytic cells that have adopted 
NC identities (Kaufman et al., 2016). The analysis of zebrafish melanomas has 
also revealed robust expression of NC genes in all melanoma cells (White et al., 
2011). In addition, I noted that genes differentially regulated in zebrafish 
melanomas compared with normal melanocytes are enriched for NC pathway 
genes. Taken together, these data indicate that zebrafish melanomas may 
resemble human melanomas that have adopted NC identities. I observed that the 
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NC gene signature identified using the zebrafish melanoma transcriptome data 
correlated with the expression of SOX10, a factor implicated in maintaining NC 
state in human melanomas (Kaufman et al., 2016; Shakhova et al., 2012). In 
addition, in the current study, patients with melanomas containing high NC gene 
signature levels had lower chances of survival. This study is the first report 
identifying a prognostic NC signature for melanomas. 
 The NC gene signature may have the potential to predict melanoma 
treatment strategies in future. Studies from the Zon lab have identified a DHODH 
inhibitor, leflunomide, which can target mechanisms common to the NC and 
melanomas (White et al., 2011). It inhibits translational elongation of c-MYC 
target genes in the NC and melanomas. Currently, the suitability of this drug for 
melanomas is being tested in clinical trials. Nevertheless, this and other drug 
targeting NC mechanisms in melanomas may be effective routes for melanoma 
therapy. Future studies should analyze whether the NC gene signature can be a 
tool for predicting the efficacy of these drugs in treating melanoma. 
 
Caveats of this study 
This study has shown that GDF6 acts as an oncogene via the BMP 
signaling pathway. However, some of the functional and mechanistic analyses 
presented in this study need further validation. Firstly, we present a model where 
GDF6-activated BMP signaling regulates both MITF and SOX9, thereby inhibiting 
melanoma cell differentiation and death, respectively. We see phoshp-
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SMAD1/5/8 binding peaks upstream of the MITF gene, which is lost upon GDF6 
knockdown. Based on this we predict direct regulation of MITF by GDF6 and 
BMP signaling. However, experiments with melanoma cells whose 
phosphoSMAD1/5/8 binding sites upstream of MITF are deleted are required to 
directly test whether BMP pathway regulates MITF. Another possibility is that 
BMP signaling regulates MITF indirectly via SOX9, as SOX9 is known to regulate 
MITF during embryogenesis (Greenhill et al., 2011). Secondly, this study does 
not exclude the possibility that GDF6-activated BMP pathway also acts via non-
canonical pathways to promote melanomas. BMP receptors are also known to 
activate phosphor p38 and JNK pathways (Pant et al., 2013; Wang et al., 2013b), 
both of which have known tumor-promoting roles in melanomagenesis. The role 
of GDF6 in melanoma cell survival is dependent on SMAD1 axis of BMP 
signaling, but the non-canonical arm of BMP signaling may be important for other 
tumor-promoting roles. Thirdly, our functional studies show Caspase 3 activation 
in melanoma cells with GDF6 knockdown. Caspase 3 activation is majorly used 
as a cell death marker, and in this study based on activation of Caspase 3 and 
other apoptotic assays like TUNEL staining and Annexin V positivity, we claim 
that GDF6 knockdown causes apoptotic death of melanoma cells. However, 
Caspase 3 also has other biological functions like regulation of differentiation of 
the hematopoietic lineage. Whether such functions are relevant to melanoma 
cells needs further testing. This would also indicate whether it is appropriate to 
use Caspase 3 as a cell death marker alone in this context. Finally, our data also 
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show that GDF6 is necessary for melanoma cell survival. Melanoma cells do not 
survive in vitro or in vivo in mouse xenografts upon GDF6 knockdown. Zebrafish 
melanoma with loss of gdf6a show increased apoptosis and reduced growth. 
Although these studies strongly suggest that GDF6 is necessary for melanoma 
cell growth and survival, direct testing using conditional GDF6 knockdown 
systems in established tumors would have been ideal.  
 
Future Directions 
This thesis has incited several fundamental questions in the fields of 
cancer biology, developmental biology, and cancer therapeutics, which will be 
answered through further research in my lab. Some of the important future 
directions are listed as follows: 
 
1) Developing Anti-GDF6 Targeting Strategies for Melanoma Therapy 
Here, I identified of a novel therapeutic target for melanoma, GDF6. In 
collaboration with MassBiologics, Boston, MA, USA, I developed monoclonal 
anti-GDF6 antibodies through hybridoma technology. Monoclonal antibodies are 
highly specific targeting molecules, suitable for therapeutic purposes. The goal of 
our collaboration was to develop antibodies that can specifically bind to GDF6 
and block its binding to BMP receptor, eventually abrogating BMP signaling. 
Through this collaboration, several antibodies have already been developed. 
Currently, their ability to bind GDF6 is being analyzed in vitro. Subsequently, the 
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efficacy of these antibodies will be analyzed in preclinical cancer models. This 
pathway has not been identified in melanomas previously, and we show that 
expression of GDF6 and activity of BMP pathway in promoting melanoma cell 
survival is independent of other known mutations like BRAF and NRAS. 
Therefore, targeting of BMP signaling can have independent effects on 
melanoma cells as compared to BRAF and MEK pathway inhibitors, and 
therefore can be used for adjuvant therapy of melanomas.  
 
2) Role of BMP Signaling in Inducing NC Identities During Melanoma Initiation 
As mentioned previously, studies have indicated the importance of NC identities 
in melanoma initiation; however, the present study implicated BMP signaling in 
invoking NC identities in melanomas. A future direction is to test whether the 
induction of NC identities during melanoma initiation is regulated directly by BMP 
signaling. This can be studied by combining the BMP reporter zebrafish 
(Tg(BRE:mCherry)) with the NC reporter (Tg(crestin:EGFP)) and monitoring in 
real-time the BMP pathway and NC identities, with respect to each other during 
tumor initiation. This can further be combined with GDF6 and BMP pathway 
modulation strategies to directly analyze the effect of the BMP pathway on NC 
identity induction during melanoma initiation. It has been difficult to understand 
how tumors initiate, in part due to the difficulty of lineage tracing studies in adult 
organisms. Here, this study provides a novel opportunity as it provides a potential 
signaling pathway that may be important for tumor initiation. This will not only 
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give us a better understanding of tumor biology, but may also be important for 
disease diagnosis. 
 
3) Role of GDF6 and BMP Signaling During Melanocyte Development 
The current study uncovered a new role of GDF6 and BMP signaling in 
melanocyte development. Nevertheless, identifying the precise function of this 
pathway may not only increase the understanding of melanocyte development 
but also provide more insight into the role of the pathway in tumorigenesis. The 
questions that need to be addressed here included the following: (1) What 
process during melanocyte development is regulated by BMP signaling—fate 
specification, differentiation, proliferation, or a combination of these? (2) Whether 
BMP signaling acts by repressing mitfa and sox9b similar to that in melanomas? 
(3) In addition to gdf6, are there other BMP ligands contributing to the role of 
BMP signaling in melanocyte development?  
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